

2025 INTERIM REPORT

CHINA MEDICAL SYSTEM HOLDINGS LIMITED
(STOCK CODE: Hong Kong: 867, Singapore: 8A8)

SGX=

DERMAVON
德镁

CONTENTS

CORPORATE INFORMATION	1
FINANCIAL HIGHLIGHTS	2
BUSINESS HIGHLIGHTS.....	3
MANAGEMENT DISCUSSION AND ANALYSIS.....	5
OTHER INFORMATION	29
CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME	33
CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION	34
CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY	36
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS	37
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS.....	38

CORPORATE INFORMATION

Board of Directors

Executive Directors

Mr. LAM Kong
Ms. CHEN Yanling

Non-Executive Director

Mr. CHEN Hongbing
(resigned on 18 August 2025)

Independent Non-Executive Directors

Mr. LEUNG Chong Shun
Ms. LUO Laura Ying
Mr. FUNG Ching Simon

Company Secretary

Ms. WU Sanyan

Authorized Representatives

Ms. WU Sanyan
Mr. LAM Kong

Audit Committee

Mr. FUNG Ching Simon (Chairman)
Mr. LEUNG Chong Shun
Ms. LUO Laura Ying

Remuneration Committee

Mr. LEUNG Chong Shun (Chairman)
Ms. LUO Laura Ying
Mr. FUNG Ching Simon

Nomination Committee

Ms. LUO Laura Ying (Chairman)
Mr. LAM Kong
Mr. LEUNG Chong Shun
Mr. FUNG Ching Simon

Environmental, Social and Governance Committee

Ms. CHEN Yanling (Chairman)
Mr. LEUNG Chong Shun
Mr. FUNG Ching Simon

Auditors

Deloitte Touche Tohmatsu
Registered Public Interest Entity Auditors

Principal Bankers

China Merchants Bank Co., Ltd.
The Hongkong and Shanghai Banking Corporation Limited
Standard Chartered Bank (Hong Kong) Limited
DBS Bank (Hong Kong) Limited

Registered Office

Maples Corporate Services Limited
PO Box 309
Ugland House
Grand Cayman, KY1-1104
Cayman Islands

Headquarters and Principal Place of Business in Hong Kong

Unit 2106, 21/F
Island Place Tower 510
King's Road
North Point, Hong Kong

Principal Contact Address in the PRC

6F - 8F, Block B, Majialong Chuangxin Building
198 Daxin Road
Nanshan District
Shenzhen 518052
Guangdong Province, the PRC

Branch Share Registrar in Hong Kong

Computershare Hong Kong Investor Services Limited
Shops 1712-1716, 17/F, Hopewell Centre
183 Queen's Road East
Wan Chai, Hong Kong

Singapore Share Transfer Agent

In.Corp Corporate Services Pte. Ltd.
36 Robinson Road
#20-01 City House
Singapore 068877

Stock Code

Hong Kong: 867
Singapore: 8A8

Company's Website

www.cms.net.cn

FINANCIAL HIGHLIGHTS

- Turnover up 10.8% to RMB4,002.0 million (H1 2024: RMB3,611.1 million); in the case that all medicines were directly sold by the Group, turnover up 8.9% to RMB4,669.6 million (H1 2024: RMB4,287.5 million)
- Gross profit up 7.2% to RMB2,891.9 million (H1 2024: RMB2,696.5 million); in the case that all medicines were directly sold by the Group, gross profit up 7.2% to RMB2,881.7 million (H1 2024: RMB2,686.9 million)
- Profit for the period up 3.1% to RMB931.5 million (H1 2024: RMB903.4 million)
- Basic earnings per share up 4.2% to RMB0.3892 (H1 2024: RMB0.3734)
- As at 30 June 2025, the Group's bank balances and cash amounted to RMB3,454.1 million while readily realizable bank acceptance bills amounted to RMB178.6 million
- Declared interim dividend per share of RMB0.1555, up 3.2% from (H1 2024: RMB0.1507)

BUSINESS HIGHLIGHTS

In the first half of 2025, CMS's business performance resumed growth. On the one hand, the significant negative impact from the National VBP products has largely diminished; on the other hand, sales of the Group's major exclusive/branded products and innovative products continued to grow, contributing 62.1% of total revenue in the case that all medicines were directly sold by the Group (H1 2024: 56.1%). Since 2025, under the theme of "New CMS, New Ascent", the Group forged ahead with steady and multi-pronged progress across several key dimensions: (1) Commercialization of innovative products continued to advance: Five approved innovative drugs accelerated the release of their commercial value; three NDAs are under review; two IND applications for in-house R&D products were approved; one consumer healthcare product received marketing approval; two new collaborative R&D innovative products were added to the portfolio; approximately 20 in-house R&D projects progressed steadily. (2) Focusing on specialty therapeutic fields, the diversified exploration of new retail, new media and consumer healthcare has begun to bear fruit: In the skin health segment with consumer attributes, Dermavon has grown into a leading innovative pharmaceutical company in China specialized in skin health, and in April 2025, it was proposed to be separately listed on the Main Board of the SEHK by way of introduction and distribution in specie. (3) A significant milestone in the "industrial internationalization" strategy: In July 2025, the Group successfully completed its secondary listing on the SGX-ST by way of introduction, which is expected to enhance its brand influence in Southeast Asia and international markets. Leveraging Singapore's strengths as an international hub, the Group has established an integrated ecosystem covering R&D, manufacturing and commercialization to capture the incremental growth potential of emerging markets and build a new multi-regional growth framework.

Three NDAs under Review

- Desidustat Tablets – a novel oral HIF-PHI for treating anaemia in non-dialysis adult CKD patients; NDA under review in China.
- Ruxolitinib cream – the first and only topical JAK inhibitor approved by the U.S. FDA and EMA for repigmentation in non-segmental vitiligo as of the end of the Reporting Period; NDA for the vitiligo indication under review in China.
- ZUNVEYL – the second oral therapy approved by the U.S. FDA for the treatment of Alzheimer's disease during the past decade, demonstrating a potentially better gastrointestinal safety profile; its NDA in China was accepted by the NMPA in July 2025.

Two IND Applications for In-house R&D Products Approved

- CMS-D001 Tablets (Highly Selective TYK2 Inhibitor) – intended for psoriasis and AD; the IND application for the AD indication was approved in China in July 2025 (the IND application for the psoriasis indication was approved in January 2024).
- CMS-D003 Capsules (Cardiac Myosin Inhibitor) – intended for the treatment of obstructive hypertrophic cardiomyopathy in adults; the IND application was approved in China in March 2025.

Two New Collaborative R&D Innovative Products Added

- In January 2025, the Group entered into a collaboration with Alpha Cognition Inc. for the improved new drug ZUNVEYL for the treatment of mild-to-moderate dementia of the Alzheimer's type, and gained an exclusive right to develop, register, manufacture, import, export and commercialize the product in Asia (excluding Japan and the Middle East region) and other designated territories.

- In January 2025, the Group entered into a collaboration with Mabgeek Biotech and its subsidiary to obtain the co-development right and exclusive commercialization right as specifically agreed upon in the agreement in Mainland China, Hong Kong, Macau, Taiwan Region and Singapore for Class 1 innovative drug MG-K10. MG-K10 is a long-acting anti-IL-4R α humanized monoclonal antibody injection, intended for type 2 inflammatory diseases including atopic dermatitis, prurigo nodularis, asthma, allergic rhinitis, etc.

One Consumer Healthcare Product Approved

- Poly-L-lactic Acid Microparticle Filler Injection obtained marketing approval from the NMPA in July 2025.

MANAGEMENT DISCUSSION AND ANALYSIS

Company Overview

China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.

Driven by a dual-engine model of collaborative R&D and in-house R&D, the Group focuses on global First-in-Class (FIC) and Best-in-Class (BIC) innovative products, efficiently advancing their clinical research, development and commercialization, enabling the continuous transformation of scientific research into clinical practices to benefit patients. As of the end of the Reporting Period, the Group’s differentiated innovation pipeline had expanded to approximately 40 products, among which five innovative drugs (covering six indications) have been approved and successfully commercialized in China.

The Group is deeply engaged in several specialty therapeutic fields and has developed proven commercialization capabilities, extensive networks and expert resources. Its major marketed products have attained leading positions in both academic and market domains. The Group continues to deepen its presence in these advantageous specialty areas, further strengthening the competitiveness of its cardio-cerebrovascular, gastroenterology, ophthalmology, and skin health businesses. Notably, the skin health business has grown into a leading innovative pharmaceutical company in China specialized in skin health and is proposed to be separately listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “SEHK”), creating scale efficiency across specialty fields.

Meanwhile, the Group is actively advancing its “industrial internationalization” strategy, continuously deepening its presence in emerging markets such as Southeast Asia and the Middle East. With Singapore as a hub, the Group has established a full pharmaceutical value chain covering R&D, manufacturing, and commercialization in the region. The completion of the Group’s secondary listing in Singapore has further enhanced its international presence and injected new momentum into its comprehensive and sustainable development.

Business Review

In the first half of 2025, China’s pharmaceutical industry continued to progress steadily along the path of high-quality development, driven by deepening policy reforms. On the one hand, National Reimbursement Drug List (“NRDL”) payment reforms have been further optimized, and the latest round of National Volume-based Procurement (“National VBP”) has adopted more refined and scientific rules, with emphasis on quality, clinical efficacy, and therapeutic options. These developments have fostered a more standardized and predictable business environment, while reinforcing a clinical value-oriented approach for pharmaceutical products. On the other hand, the innovation-driven strategy has yielded notable results: China’s innovative pharmaceutical sector has entered a period of harvest, the pace of internationalization has accelerated, and significant license-out deals have emerged frequently, showing growing global influence. Amid challenges, the industry has captured new opportunities, demonstrating strong innovation vitality and momentum for transformation and upgrading, solidifying a foundation for sustainable and healthy development.

In alignment with industry trends, the Group has continued to innovate and reshape. Since 2018, we have outlined the “New CMS” transformation roadmap, guided by the three core strategies—product innovation, commercial model reform, and international expansion. The Group has successfully evolved from “China’s largest CSO” to a “Pharma in Transition”, and is now transforming into a fully integrated innovative pharmaceutical company. This clear strategic trajectory has gradually delivered value, as the Group continues to drive synergistic growth through new products, new models, and new markets, building a “second growth curve” to promote the dual resonance of business scale and quality.

In the first half of 2025 (H1 2025), the Group's business performance resumed growth, with turnover and profit for the period increasing year-on-year (vs H1 2024):

Turnover reached RMB4,002.0 million, representing a year-on-year increase of 10.8% (H1 2024: RMB3,611.1 million). In the case that all medicines were directly sold by the Group, turnover amounted to RMB4,669.6 million, up 8.9% year-on-year (H1 2024: RMB4,287.5 million). In the case that all medicines were directly sold by the Group, sales from key non-National VBP exclusive/branded products and innovative products reached RMB2,900.0 million, representing a year-on-year growth of 20.6% (H1 2024: RMB2,404.7 million), accounting for 62.1% of total turnover. Net profit for the period was RMB931.5 million, representing a year-on-year increase of 3.1% (H1 2024: RMB903.4 million).

During the six months ended 30 June 2025 (the "Reporting Period"), the Group continued to enrich its product portfolio and expand its innovative pipeline. New innovative products obtained include ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets) and MG-K10 (an anti-IL-4R α humanized monoclonal antibody injection). The New Drug Application (NDA) for ZUNVEYL was accepted by the China National Medical Products Administration (NMPA) in July 2025. In addition, the Group's consumer healthcare product portfolio was expanded with the approval of Poly-L-lactic Acid Microparticle Filler Injection, which was approved for marketing in China in July 2025. The five innovative drugs launched previously also continued to advance in commercialization, with scale effects gradually emerging.

The Group has deepened its presence in specialty areas while actively expanding into new retail and digital media models, as well as strengthening its consumer healthcare product portfolio. The Group's skin health business, Dermavon, has demonstrated strong potential in this particular segment with consumer attributes. Dermavon is planned to be spun off and listed independently on the Main Board of the SEHK by way of introduction, and with shares distributed in specie, in order to unlock its standalone value and high growth potential.

Furthermore, on 15 July 2025, the Group successfully completed its secondary listing on the Main Board of the Singapore Exchange Securities Trading Limited (the "SGX-ST") by way of introduction. This milestone marked a new chapter in the Group's "industrial internationalization" strategy. Leveraging Singapore as a strategic hub for emerging markets, the Group has established a fully integrated "R&D – Manufacturing – Commercialization" value chain, enabling deeper engagement with incremental markets across the Asia-Pacific region and laying the foundation for multi-regional growth.

As the impact of National VBP eases and our innovative products continue to generate incremental growth, the Group's growth momentum has become increasingly solid. Looking ahead, the Group will remain committed to differentiated innovation, unlock the commercial potential of a diversified ecosystem, and accelerate its pace of internationalization, thereby fueling high-quality development. The Group is moving towards becoming an innovation-driven, multinational pharmaceutical company rooted in China and expanding across emerging markets, with a fully integrated R&D, manufacturing, and commercialization value chain to deliver high-quality pharmaceutical products and services to patients worldwide.

I. Innovation Driving Quality Growth

Topping the three core strategies, the "Innovation-driven" strategy leverages a three-dimensional innovation mechanism of "Overseas Licensing, Domestic Collaboration, and In-house R&D" to continuously introduce high-value pipelines to the Group, solidifying the foundation for short-, medium-, and long-term sustainable growth. Concurrently, the Group continually upgrades its lifecycle management system covering "target discovery, clinical development, regulatory approval and commercialization" to establish an efficient innovation closed-loop that accelerates patients' access to global FIC and BIC therapies.

As of the end of the Reporting Period, the Group has deployed approximately 40 differentiated innovative pipeline products, among which, five innovative drugs (ILUMETRI, VELPHORO, METOJECT, VALTOCO and LUMEBLUE), have been approved for marketing in China and entered commercialization; two innovative drugs (Desidustat Tablets and ruxolitinib phosphate cream (“ruxolitinib cream”) - vitiligo indication) were in the NDA review stage in China; approximately 10 projects have been prepared/launched for the registrational clinical trials, mainly randomized controlled trials (RCT), and about 20 in-house R&D projects were progressing steadily, five of which have entered clinical development stage.

1. Innovative Products of CMS

1.1 Innovative Drugs Approved for Marketing in China and Entered Large-Scale Clinical Application

- **VELPHORO (Sucroferriic Oxyhydroxide Chewable Tablets) – China’s first iron-based, non-calcium phosphate binder (PB), providing potent phosphorus reduction with lower pill burden, and improving nutritional status in patients; in the Category B of NRDL**

In 2023, VELPHORO was approved for marketing in China for the control of serum phosphorus (sP) levels in adults with chronic kidney disease (CKD) on hemodialysis or peritoneal dialysis, and filled the gap of phosphorus-lowering treatment for Chinese paediatric patients aged 12 to 18 years old with CKD stages 4–5 or CKD on dialysis.

It is demonstrated in multiple global clinical studies, real-world study (RWS) data and the Chinese instruction that compared with other PBs, patients maintained on VELPHORO used about 50% fewer PB pills/day, and the proportion of patients achieving target sP increased by 95%. VELPHORO has characteristics of good safety and patient compliance without risk of calcium and heavy metal accumulation. In addition, it holds the advantages of unaffected absorption of oral liposoluble vitamin D, maintaining stable iron parameters, improving the nutritional status in patients, etc.

During the Reporting Period, the Group actively responded to the National Health Commission’s call to prioritize “improving sP control rates in patients on dialysis” as a key quality control improvement target. The Group conducted physician education programs to raise patients’ awareness of sP management and established it as a leading brand in the dialysis hyperphosphatemia treatment field by leveraging its core advantage of “achieving target with good sP levels reduction”.

- **METOJECT (Methotrexate Injection) – China’s first pre-filled Methotrexate (MTX) Injection for subcutaneous administration for the treatment of psoriasis and RA; in the Category A of NRDL**

In 2023, METOJECT was approved for marketing in China for the treatment of severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of therapy such as phototherapy, PUVA, and retinoids. In 2024, its core indication -- active rheumatoid arthritis (RA) in adult patients -- was approved for marketing in China.

The bridge clinical trial of METOJECT’s RA indication in China aimed to compare the changes of DAS28-ESR score of patients with RA treated by the product and methotrexate tablets compared with the baseline, and to judge whether the non-inferiority is established. The study reached the preset primary endpoint, and the experimental group (given the product) was not inferior to the control group (given methotrexate tablets). In addition, the results of secondary efficacy indicators suggest that the efficacy of the product is significantly better than that of methotrexate tablets or there is a trend of better. The results also show that some of the curative effects that can be observed in the early stage of the product are more obvious than those of methotrexate tablets, suggesting that the curative effect of the product appears earlier. The product has some advantages over methotrexate tablets in gastrointestinal safety. The results were published in the academic journal *Rheumatology* in March 2025.

During the Reporting Period, the Group reinforced METOJECT's academic position as the first-line treatment and anchor combination therapy for RA, and accelerated market access across hospital and out-of-hospital channels, to drive market share growth. Meanwhile, the Group positioned METOJECT as a standardized first-line therapy for RA by leveraging its core advantage of "rapid onset and target achievement", combined with differentiated advantages of subcutaneous administration, low dosage formulation, no need for reconstitution and convenient injection. During the Reporting Period, the product was included in the "Consensus on early diagnosis and treatment of psoriatic arthritis (2025)" published by *Chinese Journal of Rheumatology* and "EULAR Recommendations for the Management of Rheumatoid Arthritis-2025 Update" published by the *European Alliance of Associations for Rheumatology (EULAR)*.

- **VALTOCO (Diazepam Nasal Spray) – China's first Diazepam Nasal Spray, which can be administered anytime and anywhere, and meets clinical needs for accessible and convenient treatment option for seizure clusters of patients with epilepsy; in the Category B of NRDL**

In 2023, VALTOCO was approved for marketing in China for the acute treatment of seizure clusters/acute repetitive seizures in patients with epilepsy 6 years of age and older. In June 2025, the Supplemental New Drug Application to expand the approved indication to include "patients with epilepsy 2 years of age and older" was accepted by the China NMPA. The product is administered through the nasal mucosa, with high bioavailability, outstanding absorbability, tolerability and reliability.

During the Reporting Period, focusing on VALTOCO's unique clinical value of "Pre-Hospital Seizure Rescue with Convenience", the Group conducted expert case seminars and participated in establishing the "CAAE Epilepsy Care Fund" to promote discussion and training on epilepsy prevention and management, and to strengthen emergency treatment needs for seizure episodes. Concurrently, the Group also actively advanced post-marketing RWS to generate more medical evidence for the product.

- **LUMEBLUE (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) – China's first Methylthioninium Chloride Enteric-coated Sustained-release Tablets, providing a novel approach that enhances diagnosis sensitivity in detecting lesions during colonoscopy**

In 2024, LUMEBLUE was approved for marketing in China to enhance visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy. The results of the Phase III clinical trial in China showed that LUMEBLUE can significantly improve the detection rate of non-polypoid colorectal lesions (the primary endpoint of the study), leading to an improved detection rate of dangerous lesions such as non-polypoid adenomas (the secondary endpoint).

During the Reporting Period, the Group continued to advance LUMEBLUE's market access development across multiple channels, actively conducted post-marketing clinical trials to enrich medical evidence, and established the product's recognition as a "pain-free colonoscopy package medication" through academic promotion.

1.2 Innovative Drugs in the NDA Review Stage in China

- **Desidustat Tablets – A novel oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor (HIF-PHI)**

During the Reporting Period, the China NDA for Desidustat Tablets for treating anaemia in non-dialysis adult CKD patients was under review by the Center for Drug Evaluation (CDE) (the NDA was submitted in April 2024).

The China Phase III clinical trial of Desidustat Tablets has demonstrated positive results. The primary endpoint of the haemoglobin (Hb) mean change from baseline to the period of Week 7–9 has indicated that, Desidustat is more effective than placebo in increasing Hb level. The product is administrated orally, thus expecting to improve the treatment compliance of patients and to meet the unmet treatment needs in the field of CKD anaemia, including both dialysis and non-dialysis patients.

1.3 Innovative Drugs in Clinical Development in China

- ***Y-3 for Injection – An original unimolecular Class 1 innovative drug, which is the only non-peptide PSD95/nNOS uncoupler that has entered clinical development, with potential to become the first dual-function brain cytoprotectant for treating ischemic stroke while preventing post-stroke depression and anxiety; China Phase III clinical trial completed***

Y-3 for Injection is used to alleviate neurological symptoms and dysfunction of daily activities caused by acute ischemic stroke. If approved for marketing, it is expected to be the first brain cytoprotectant with a clearly-defined target. As of the end of the Reporting Period, Y-3 for Injection has successfully completed the China Phase III clinical trial.

As the world's first brain cytoprotectant developed upon PSD-95/ nNOS and α_2 -GABA_AR, the key targets for stroke and post-stroke affective disorders, Y-3 for Injection acts on multiple key pathological processes in the ischemic cascade of ischemic stroke. Through highly selective multi-targets synergy, it is conducive to exerting brain cytoprotection effects, demonstrating superior efficacy for ischemic stroke and potential prevention of post-stroke depression and anxiety complications. Meanwhile, unlike Nerinetide, the product has no risk of degradation by plasmin, which allows combination therapy with thrombolytics and has fewer future clinical treatment limitations, benefiting more patients.

The results of Phase II clinical trial of the product for the treatment of acute ischemic stroke was presented as an oral poster at the 10th European Stroke Organisation Conference in 2024 (ESOC 2024). It indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (20mg, 40mg, 60mg, qd) demonstrated a significantly higher proportion of patients achieving a favorable functional outcome at 90 days than those in the placebo group (20mg: 67.8% vs 60.7%, 40mg: 76.7% vs 60.7%, 60mg: 70.0% vs 60.7%). Moreover, the product showed comparable safety to placebo in acute ischemic stroke patients, exhibiting good tolerability.

- ***ABP-671 – A Urate Anion Transporter 1 (URAT1) Inhibitor, anticipated to offer more effective and safer treatment alternatives for patients suffering from gout and hyperuricemia***

ABP-671 is an oral small molecule Class 1 innovative drug, which modifies the parent nuclide's molecular scaffold and electron cloud distribution of benzbromarone, forming a highly rigid structure that resists metabolism and existing predominantly as the original drug without generating toxic quinone metabolites. The products' preclinical and clinical trials have demonstrated good safety profile with no observed hepatotoxicity. The product can be administered at lower doses while reducing uric acid to lower levels, and has gout-tophus dissolution capability. As of the end of the Reporting Period, the China Phase IIb/III clinical trial for ABP-671 was advancing steadily.

The China Phase IIa clinical trial of the product successfully achieved its endpoints. At a dose 1 mg group of ABP-671, over 86% of the subjects with gout or hyperuricemia achieved the primary endpoint (sUA levels <6 mg/dL or 360 μ mol/L). At other doses, 100% of subjects achieved the primary endpoint (sUA levels <6 mg/dL). At doses of 6 mg group and 12 mg group, 100% of subjects achieved sUA levels <5 mg/dL (300 μ mol/L); and there were 57% and 100% of subjects achieved sUA levels <4 mg/dL (240 μ mol/L), respectively. No significant adverse events have occurred, and ABP-671 is well tolerated.

Major In-house R&D Pipelines

- ***CMS-D002 Capsules (GnRH Receptor Antagonist)***

As of the end of the Reporting Period, a randomized, double-blind, placebo-controlled Phase I clinical study of single or multiple dose escalation to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of the product in healthy adult premenopausal female subjects, was progressing smoothly. The product may be developed to treat endometriosis, uterine fibroids, prostate cancer, and other diseases in the future.

- ***CMS-D005 Injection (GLP-1R/GCGR Dual Agonist)***

As of the end of the Reporting Period, a Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profile of the product in healthy and overweight/obese adult subjects in China, was progressing smoothly. The product may also be developed in the future to treat metabolic dysfunction-associated steatohepatitis, type 2 diabetes and other metabolism-related diseases.

- ***CMS-D003 Capsules (Cardiac Myosin Inhibitor)***

In March 2025, the product was granted approval for Investigational New Drug (“IND”) in China to conduct a clinical trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the product in both healthy adults and adult patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in China. The product may also be developed for the treatment of heart failure with preserved ejection fraction in the future.

1.4 Replenishment of Pipeline

- ***ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets) – As the second oral therapy approved by the U.S. Food and Drug Administration (FDA) for the treatment of Alzheimer’s disease during the past decade, it demonstrates a potentially better gastrointestinal safety profile to improve compliance of patients***

In January 2025, the Group entered into a License, Collaboration and Distribution Agreement with Alpha Cognition Inc. of the improved new drug ZUNVEYL for the treatment of mild-to-moderate dementia of the Alzheimer’s type, and gained an exclusive right to develop, register, manufacture, import, export and commercialize the product in Asia (excluding Japan and the Middle East region) and other designated territories.

In July 2025, the China NDA for ZUNVEYL was accepted by the NMPA for the treatment of mild-to-moderate dementia of the Alzheimer’s type in adults.

As a new generation of acetylcholinesterase inhibitor (AChEI), ZUNVEYL can inhibit the acetylcholinesterase from breaking down the neurotransmitter acetylcholine, increase the level of acetylcholine in the central nervous system, and therefore alleviate cognition and memory impairment in Alzheimer’s disease patients. As a prodrug of galantamine, ZUNVEYL remains inert as it passes through the stomach and the intestine, and eventually releases the active drug into the bloodstream after being metabolized by the liver. It is expected to have equivalent efficacy as galantamine with the potential of reducing gastrointestinal (GI) side effects and addressing certain tolerability issues. Galantamine has accumulated extensive evidence of efficacy and demonstrated long term clinical benefit in the treatment of mild-to-moderate dementia of the Alzheimer’s type since the approval of FDA in 2001. Moreover, GI adverse events documented across all studies for ZUNVEYL were less than 2% and no insomnia was observed.

- ***MG-K10 (asthma and seasonal allergic rhinitis indications, etc.) –as of the end of the Reporting Period, the product is the only long-acting anti-IL-4R α monoclonal antibody to have entered pivotal clinical stages worldwide (one dose every four weeks)***

In January 2025, the Group entered into a Collaboration Agreement (the “Agreement”) with Hunan Mabgeek Biotech Co., Ltd. (“Mabgeek Biotech”) and its subsidiary for Class 1 innovative drug anti-IL-4R α humanized monoclonal antibody injection MG-K10, and obtained the co-development right and exclusive commercialization right as specifically agreed upon in the Agreement to the product in Mainland China, Hong Kong Special Administrative Region (“Hong Kong”), Macau Special Administrative Region (“Macau”), Taiwan Region and Singapore.

MG-K10 simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13. Following Fc mutation, it allows long dosing interval owing to its prolonged half-life, and it is expected to be the first long-acting anti-IL-4R α monoclonal antibody marketed in China. MG-K10 is used for the treatment of type 2 inflammatory diseases, including dermatology indications and non-dermatology indications (asthma, allergic rhinitis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, chronic obstructive pulmonary disease, etc.). The rights of dermatology indications in Mainland China belong to Dermavon, while the rights outside Mainland China and the rights of non-dermatology indications belong to the Group (excluding Dermavon).

As of the end of the Reporting Period, the China Phase III clinical trial for asthma indication and the China Phase II clinical trial for seasonal allergic rhinitis indication were progressing smoothly. Additionally, the product has obtained IND approvals for eosinophilic esophagitis and chronic rhinosinusitis with nasal polyps in China. (*Note: See “Section 2. Innovative Products of Dermavon - 2.4 Replenishment of Pipeline” for more information about progress on dermatology indications*)

2. Innovative Products of Dermavon

2.1 Innovative Drugs Approved for Marketing in China and Entered Large-Scale Clinical Application

- ***ILUMETRI (Tildrakizumab Injection) - a monoclonal antibody specifically targeting to the p19 subunit of IL-23, requires only 4 administrations per year during its maintenance period for the treatment of psoriasis, which may lead to higher patient compliance; in the Category B of NRDL***

In 2023, ILUMETRI was approved for marketing in China for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Compared to IL-17, ILUMETRI targets the upstream IL-23, which can lead to a more comprehensive suppression of inflammatory pathway and reduce the risk of resistance associated with long-term medication. It demonstrates good efficacy in providing sustained response and long-term remission, with good tolerability and safety, offering patients a new sustainable treatment option. Additionally, the product has been recommended as a first-line treatment option by several domestic and international guidelines.

The results from a Phase III clinical trial in China for the basic and extended study of ILUMETRI demonstrated that the product’s primary efficacy assessment indicator PASI 75 response rate continued to increase over treatment time. The PASI 75 response rate reached a high level after 28 weeks of treatment with ILUMETRI and maintained at 91.3% at week 52, and the product showed good long-term safety and tolerance. The results were published by the academic journal *Chinese Medical Journal*.

During the Reporting Period, Dermavon implemented medical-evidence-driven promotion, including large-scale RWS and the establishment of scientific research platforms. By accumulating medical evidence, Dermavon gradually built brand recognition for the product and accelerated its penetration and volume growth in both hospitals and dual-channel pharmacies. During the Reporting Period, the product was newly included in the “Interleukin-23p19 inhibitors for the treatment of moderate-to-severe psoriasis: an expert opinion of real-world evidence studies in Europe” published by *the Journal of Dermatological Treatment* and the “Expert consensus on the treatment of dermatoses with targeted drugs (2025 version)” published by *the Chinese Journal of Dermatology*.

2.2 Innovative Drugs in the NDA Review Stage in China

- ***Ruxolitinib cream — as of the end of the Reporting Period, the product is the first and only topical JAK inhibitor approved by the U.S. FDA and the European Medicines Agency (EMA) for repigmentation in non-segmental vitiligo, and is expected to become the first approved treatment for vitiligo in China***

Treatment of Vitiligo

As of the end of the Reporting Period, the China NDA for ruxolitinib cream for the topical treatment of non-segmental vitiligo in adults and adolescents aged 12 and above was under review by the CDE.

As for reducing the area of vitiligo lesions and repigmenting the skin, the treatment effect of ruxolitinib cream continued to improve with longer treatment duration. Two pivotal clinical studies conducted by Incyte overseas showed that after 24 weeks of treatment, compared with vehicle, the facial and total body repigmentation of patients treated with ruxolitinib cream was significantly improved, and the primary endpoint of efficacy (F-VASI 75) was 29.9%. The 52-week F-VASI 75 data showed improvement in repigmentation with the extension of treatment, with 50% of patients meeting the F-VASI 75 endpoint at week 52. Additionally, ruxolitinib cream was analyzed in a RWS in China. The results showed positive efficacy, which is consistent with the key outcomes of global pivotal clinical studies. During the Reporting Period, the results of the China RWS were published in *The Journal of the American Academy of Dermatology (JAAD)*, a leading international dermatology journal.

During the Reporting Period, Dermavon has participated in establishing China Vitiligo Research Alliance and conducting vitiligo natural history study. Dermavon has also actively advanced the pilot use of the product in Hainan Boao Lecheng International Medical Tourism Pilot Zone (the “Lecheng Pilot Zone”), and designated medical institutions in Guangdong Province of the Greater Bay Area. As of the end of the Reporting Period, over 6,000 patients in Boao Lecheng Super Hospital have used innovative drug ruxolitinib cream. Meanwhile, a total of 17 designated hospitals in cities of the Greater Bay Area, such as Guangzhou, Shenzhen, Zhuhai, Zhongshan, Dongguan and Foshan were able to prescribe innovative drug ruxolitinib cream to patients. During the Reporting Period, the product was newly included in the “Expert consensus on the treatment of dermatoses with targeted drugs (2025 version)” and “Guideline on phototherapy for vitiligo (2025 edition)” published by *the Chinese Journal of Dermatology*.

Treatment of Atopic Dermatitis (AD)

During the Reporting Period, Dermavon was steadily advancing a randomized, double-blind, placebo-controlled Phase III bridging trial evaluating the efficacy and safety of ruxolitinib cream in the treatment of AD in Chinese population. According to two pivotal overseas studies conducted by Incyte, treatment with ruxolitinib cream resulted in a significant proportion of patients who achieved the primary efficacy endpoint of clear or almost clear and a significant reduction in pruritus compared to the vehicle group. Ruxolitinib cream was also well-tolerated at all dosage strengths and was not associated with clinically-significant application site reactions. Based on the safety and efficacy data, ruxolitinib cream can potentially provide AD patients a better alternative novel treatment.

2.3 Innovative Drugs in Clinical Development in China

- ***Povorcitinib - a selective oral small-molecule JAK1 Inhibitor, with the potential to provide a new treatment option for patients suffering from autoimmune and inflammatory dermatologic diseases***

In June 2025, the IND application of povorcitinib for nonsegmental vitiligo and hidradenitis suppurativa (HS) was accepted in China, and the clinical development is planned to initiate after IND approvals.

Povorcitinib offers a potential oral treatment option for nonsegmental vitiligo patients, particularly those with extensive vitiligo. HS has been included in the second batch of the Rare Disease List in China. As a chronic inflammatory dermatologic disease, it can have a profoundly negative impact on patients' quality of life.

As of the end of the Reporting Period, Incyte was advancing the Phase III clinical trials of povorcitinib for nonsegmental vitiligo and prurigo nodularis (PN), as well as Phase II clinical trials for chronic spontaneous urticaria (CSU) and asthma in several countries outside China. It also announced the positive topline results from two Phase III clinical trials for HS. In the completed clinical trials, povorcitinib has shown potential for efficacy and safety in adult patients with moderate to severe HS.

Major In-house R&D Pipelines

- ***CMS-D001 Tablets (Highly Selective TYK2 Inhibitor)***

In July 2025, the NMPA grants the consent to conduct a clinical trial evaluating the safety and efficacy of CMS-D001 for the treatment of AD. Additionally, the product was advancing a randomized, double-blind, placebo-controlled phase I clinical study of single or multiple dose escalation and food effects (open) to evaluate the safety, tolerability, pharmacokinetics and efficacy of the product in healthy subjects and patients with plaque psoriasis. In addition to psoriasis and AD, the product is also planned to be developed for the treatment of immune-inflammatory diseases such as systemic lupus erythematosus in the future.

2.4 Replenishment of Pipeline

- ***MG-K10 (atopic dermatitis and prurigo nodularis indications, etc.) – as of the end of the Reporting Period, the product is the only long-acting anti-IL-4R α monoclonal antibody to have entered pivotal clinical stages worldwide (one dose every four weeks)***

In January 2025, the Group entered into a collaboration agreement with Mabgeek Biotech in respect of MG-K10. Dermavon obtained the co-development right (except for AD) and the exclusive commercialization right to the product in respect of dermatology indications in Mainland China. In accordance with the agreement, Mabgeek Biotech is responsible for progressing the clinical trial for AD; whereas both parties will be jointly responsible for progressing the clinical development for PN in adults and other indications in the field of dermatology.

As of the end of the Reporting Period, MG-K10 has completed 16 weeks of treatment for all subjects in the China Phase III clinical trials for the treatment of AD in adults, and MG-K10 was also making steady progress with subject enrollment for the China Phase III clinical trial for PN. In the completed Phase II clinical trials for adult moderate-to-severe AD, MG-K10 has demonstrated good efficacy and safety. The percentage change of Eczema Area and Severity Index (EASI) from baseline at week 16 was measured as the primary endpoint. It is reported that the least squares mean percent changes in EASI from baseline in the groups of 150 mg every 4 weeks (Q4W), 300 mg Q4W, 300 mg Q2W, or placebo, were -58.7%/-81.6%/-69.8%/-42.7%, respectively ($P=0.076$ / $P<0.001$ / $P=0.003$ vs. placebo), demonstrating potential efficacy in the treatment of moderate-to-severe AD. Serious adverse events (AEs) and AE-related treatment discontinuations were rare.

3. Innovative Pipeline

Launched Overseas/China or Under Marketing Application Review

Product	Rights Authorized Region*	Indication	Clinical Trial Approval	Clinical Trial for Registration	Marketing Application	Marketed	Major Marketed Regions*			
							CN	US	EU	JP
Diazepam Nasal Spray		For the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e. seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 6 years of age and older					 2023.6			
		For the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e. seizure clusters, acute repetitive seizures) that are distinct from a patient's usual seizure pattern in patients with epilepsy 2-5 years of age								
Tildrakizumab Injection (Biological Agent)		For the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy					 2023.5			
Methotrexate Injection		Severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of therapy such as phototherapy, PUVA, and retinoids					 2023.3			
		Active rheumatoid arthritis in adult patients					 2024.7			
Methylthioninium Chloride Enteric-coated Sustained-release Tablets		A diagnostic agent to enhance visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy					 2024.6			
Ruxolitinib cream		Topical treatment of nonsegmental vitiligo in adult and pediatric patients 12 years of age and older					Marketing Approval in Macau (2024.4) and HK(2024.11)			
		Topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 12 years of age and older whose disease is not adequately controlled with topical prescription therapies, or when those therapies are not advisable								
Desidustat Tablets		For treating anaemia in non-dialysis adult, Chronic Kidney Disease (CKD) patients								
Cyclosporine Eye Drops 0.09%		Increasing tear secretion in patients with keratoconjunctivitis sicca (dry eye)								
Latanoprost Eye Drops		Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension								
ZUNVEYL		For treating mild to moderate dementia of the Alzheimer's type in adults								
Levetiracetam XR Tablet		Adjunctive therapy for the treatment of partial-onset seizures								
BCG for Intravesical Instillation (Biological Agent)		Non-invasive urothelial bladder carcinoma, including curative treatment of carcinoma in situ and prophylactic treatment of recurrence								

Marketed in China Under R&D in China Overseas

Designated Asian Regions Mainland China, Hong Kong, Macau and Taiwan Designated Asia-Pacific Regions

* Major Marketed Regions indicate where products are approved. CMS's rights are stated by Rights Authorized Region. CMS has NO development, commercialization or other product rights in unauthorized regions.

** The rights authorized region of ZUNVEYL includes Asia (excluding Japan and the Middle East region) and other designated territories. In July, the NDA of ZUNVEYL was accepted in China.

*** Taiwan Region is not included in the rights authorized region of BCG for Intravesical Instillation.

Please refer to local prescribing information for more information, including full safety information, on CMS's marketed medicines, or on medicines marketed by CMS's collaboration partners.

Under R&D Stages

Product	Rights Authorized Region*	Indication	Pre-clinical	Clinical Trial Approval	Phase I	Phase II	Phase III	Marketing Application*
SDN-037		Eye pain and inflammation after cataract surgery						
PDP-716		Reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension						
CF101		Psoriasis						
povorcitinib		Non-segmental vitiligo, Hidradenitis suppurativa, Prurigo nodularis						
		Asthma, Chronic spontaneous urticaria						
CF102		Hepatocellular carcinoma						
		Non-alcoholic fatty liver disease / non-alcoholic steatohepatitis						
XF-73		Prevention of post-surgical staphylococcal infections						
Y-3 for Injection	**	Used to alleviate neurological symptoms and dysfunction of daily activities caused by acute ischemic stroke						
ABP-671	**	Gout						
Anti-IL-4R α Humanized Monoclonal Antibody Injection (MG-K10)		Atopic Dermatitis, Asthma, Prurigo Nodularis						
		Seasonal Allergic Rhinitis						
		Eosinophilic Esophagitis, Chronic Rhinosinusitis with Nasal Polyps						
VEGFA/ANG2 Tetraivalent Bispecific Antibody (Biological Agent)		Intended for ocular fundus neovascular diseases						
TYK2 Inhibitor (CMS-D001) #		Intended for psoriasis						
		Intended for atopic dermatitis						
GnRH Receptor Antagonist (CMS-D002)		Intended for the treatment of moderate to severe pain associated with endometriosis						
GLP-1R/GCGR Dual Agonist (CMS-D005)		Intended for obesity/overweight						
Cardiac Myosin Inhibitor (CMS-D003)		Intended for hypertrophic cardiomyopathy						
~15 Self-developed Innovative Drugs								

China Overseas

Global

Designated Asian Regions

Mainland China, Hong Kong, Macau and Taiwan

* CMS's rights are stated by Rights Authorized Region. CMS has NO development, commercialization or other product rights in unauthorized regions.

** Taiwan Region is not included in the rights authorized region.

The IND application of CMS-D001 for the AD indication was approved in China in July.

Please refer to local prescribing information for more information, including full safety information, on CMS's marketed medicines, or on medicines marketed by CMS's collaboration partners.

II. Commercialization System

The Group remains committed to addressing unmet medical needs through products with academic and medical differentiation. We continue to promote post-marketing clinical research (including RWS) and academic platform development, to drive the commercial value realization of innovative drugs and key exclusive/branded products through medical evidence. We are also continuously enriching our promotional and sales channels—establishing an omnichannel model of “in-hospital + out-of-hospital” engagement, a comprehensive “online + offline” marketing system, and a diversified product portfolio with consumer attributes. With a professional promotion team possessing high execution capabilities, we aim to accelerate market penetration and value delivery with enhanced efficiency and expertise.

As of the end of the Reporting Period, the Group had a promotion network covering over 50,000 hospitals and medical institutions, and approximately 300,000 retail pharmacies in China.

1. Marketed Products

The Group’s major marketed products have covered the cardio-cerebrovascular, gastroenterology, skin health, ophthalmology and other related areas. As of the end of the Reporting Period, a summary of the information of major products is as follows:

Product line	Product	Indication/Function	Product Advantage
Cardio-cerebrovascular Related Field Line	VELPHORO (Sucroferric Oxyhydroxide Chewable Tablets) (innovative drug)	For the control of sP levels in adults with CKD on hemodialysis or peritoneal dialysis, and for the control of sP levels in paediatric patients 12 years of age and older with CKD stages 4-5 or CKD on dialysis	China’s first iron-based, non-calcium phosphate binder, providing potent phosphorus reduction with lower pill burden, and improving nutritional status in patients
	VALTOCO (Diazepam Nasal Spray) (innovative drug)	For the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e. seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 6 years of age and older	China’s first Diazepam Nasal Spray, which can be administered anytime and anywhere, and meets clinical needs for accessible and convenient treatment option for seizure clusters of patients with epilepsy
	XinHuoSu (Recombinant Human Brain Natriuretic Peptide for Injection)	Acute decompensated heart failure	The first Recombinant Human Brain Natriuretic Peptide (rhBNP) medicine approved by the China NMPA
	Plendil (Felodipine Sustained Release Tablets)	Hypertension and stable angina pectoris	Original reference preparation, the Calcium Channel Blocker (CCB) medicine suitable for Chinese patients, providing cardio-cerebrovascular protection and high vascular selectivity
	Deanxit (Flupentixol and Melitracen Tablets)	Mild-to-moderate depression, anxiety and psychosomatic affections	Original reference preparation, the preferred medicine for mild to moderate anxiety and depression

MANAGEMENT DISCUSSION AND ANALYSIS
(CONTINUED)

Gastroenterology/ Autoimmune Related Field Line	METOJECT (Methotrexate Injection) (innovative drug)	For the treatment of severe recalcitrant disabling psoriasis, which is not adequately responsive to other forms of therapy such as phototherapy, PUVA, and retinoids; Active rheumatoid arthritis in adult patients	China's first pre-filled MTX Injection for subcutaneous administration for the treatment of psoriasis and RA
	LUMEBLUE (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) (innovative drug)	A diagnostic drug used for enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy	China's first Methylthioninium Chloride Enteric-coated Sustained-release Tablets, providing a novel approach that enhances diagnosis sensitivity in detecting lesions during colonoscopy
	Ursofalk (Ursodeoxycholic Acid Capsules)	Cholesterol gallstones in the gallbladder, cholestatic liver disease and biliary reflux gastritis	Original reference preparation, the preferred first-line medicine for cholestatic liver disease
	Salofalk (Mesalazine)	Ulcerative colitis, including the treatment of acute exacerbations and the maintenance treatment to prevent recurrence, as well as the treatment of acute exacerbations of Crohn's disease	Original reference preparation, ranking the first in the market share of aminosalicylic acid, a first-line treatment for inflammatory bowel disease in China according to 2024 IQVIA data
	Bioflor (Saccharomyces Boulardii Sachets) (exclusive product)	Diarrhea in adults and children, as well as diarrhea symptoms induced by intestinal flora disturbance	Probiotics preparations with abundant medical evidence and high-level recommendations from authoritative domestic and overseas guidelines
	Combizym (Oryz-aspergillus Enzyme and Pancreatin Tablets) (exclusive product)	Dyspepsia caused by a decrease in digestive enzymes	Effective in both stomach and intestines, the recommended digestive enzyme preparation for the replacement therapy of pancreatic exocrine insufficiency
	Cidine (Cinitapride Hydrogen Tartrate Tablets) (exclusive product)	Improve the symptoms of early satiety, postprandial fullness discomfort, and abdominal distension in mild to moderate functional dyspepsia	Dual target prokinetic agent, first-line drugs for functional dyspepsia

Dermatology Related	ILUMETRI (Tildrakizumab Injection) (innovative drug)	For the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy	A monoclonal antibody specifically targeting to the p19 subunit of IL-23, requires only 4 administrations per year during its maintenance period for the treatment of psoriasis, which may lead to higher patient compliance
	Hirudoid (Mucopolysaccharide Polysulfate Cream) (exclusive product)	Blunt traumata with and without hematomas, and superficial phlebitis that cannot be treated by compression	Repair agent for skin barrier with multiple functions
	Aethoxysklerol (Polidocanol Injection)	Different specifications for sclerotherapy of different varicose veins, including spider veins, central veins of spider veins, and medium to large varicose veins	Original reference preparation, a German original brand for the treatment of sclerotherapy of varicose veins with years of clinical application
Dermatology-Grade Skincare Product	Hirudoid® Azelaic Acid Skincare Series (including 5 products)	Acne-prone skin care, prevention, and improvement of acne	Extension of the Hirudoid brand, to create a professional acne-care portfolio
	Heling Soothing Product Series (including 4 products)	Skin soothing with a combination of cleansing and moisturizing which is suitable for sensitive skin	Composed of four core ingredients that can moisturize and soothe the skin, helping to repair the skin barrier
Ophthalmology Line	Augentropfen Stulln Mono Eye Drops (Esculin and Digitalisglycosides Eye Drops) (exclusive product)	Senile macular degeneration and all forms of asthenopia	The representative medicine for the treatment of asthenopia and the safe and convenient treatment option of senile macular degeneration
	EyeOP1 Glaucoma Treatment Device (exclusive product)	Glaucoma with intraocular pressure that cannot be controlled by drugs and surgery	Using high-focused ultrasound technology, which is a non-invasive procedure with precise targeting and convenient operations, providing a safe and effective innovative treatment for glaucoma
Other Major Products	Elcitonin (Elcatonin Injection)	Osteoporosis pain	Original reference preparation, quick onset, with long-term use and good safety, for the treatment of osteoporosis pain
	Vmonalisa (Modified Sodium Hyaluronate Filler for Injection)	Used for mid to deep dermal implantation for the correction of moderate to severe nasolabial folds (medium and macro particle); Used for the deep dermal to subcutaneous implantation for the correction of moderate to severe nasolabial folds (small particle)	Painless, fashionable and accessible luxury HA filler with multiple particle sizes from South Korea, featured with safety and natural looking

During the Reporting Period, the revenue of major products by product line was as follows:

- The products under cardio-cerebrovascular related field line recorded a revenue of RMB1,538.0 million, an increase of 1.4% compared with the same period last year. In the case that all medicines were directly sold by the Group, the revenue of products under cardio-cerebrovascular related field line would increase by 0.6% to RMB2,215.8 million compared with the same period last year, accounting for 47.5% of the Group's revenue in the case that all medicines were directly sold by the Group.
- The revenue of products under gastroenterology/autoimmune related field line increased by 4.9% to RMB1,411.1 million compared with the same period last year, accounting for 30.2% of the Group's revenue in the case that all medicines were directly sold by the Group.
- The revenue of the products under skin health line (Dermavon) increased by 104.3% to RMB498.0 million compared with the same period last year, accounting for 10.7% of the Group's revenue in the case that all medicines were directly sold by the Group.
- The revenue of the products under ophthalmology line increased by 17.7% to RMB358.1 million compared with the same period last year, accounting for 7.7% of the Group's revenue in the case that all medicines were directly sold by the Group.
- Other products recorded a revenue of RMB196.8 million, a decrease of 1.9% compared with the same period last year. In case that all medicines were directly sold by the Group, the revenue would decrease by 2.3% to RMB186.6 million compared with the same period last year, accounting for 3.9% of the Group's revenue in the case that all medicines were directly sold by the Group.

III. Skin Health Business (Proposed to Be Spun off and Separately Listed on the SEHK)

Dermavon is a leading innovative pharmaceutical company in China specialized in skin health, with unified operations combining the R&D, production, and sales of dermatological prescription products and dermatology-grade skincare products. It is committed to providing comprehensive skin health solutions, from prevention to treatment and long-term care. Since commencing independent operations in 2021, Dermavon has achieved dual leadership in both the "coverage of dermatology indications" and the "revenue scale of dermatological prescription drugs" within four years. Dermavon has developed a diversified and differentiated product portfolio and strong synergies in the field of skin health. Leveraging the industry-leading commercialization capabilities, it is leading the continuous innovation of skin health treatment and care, unlocking the vast market potential of skin health products.

During the Reporting Period, the Group proposed to spin-off and separately list Dermavon on the Main Board of the SEHK by way of introduction and distribution in specie, aiming to fully unlock the high-growth potential and standalone value of its skin health business.

1.Comprehensive and Diversified Product Portfolio, Specializing in Dermatology

Focusing on the major dermatological diseases, Dermavon has deeply developed dermatological prescription products with different mechanisms of action and treatment modalities. Leveraging this foundation, Dermavon is expanding its product portfolio from "treatment" to "care" in skin health, dedicated to creating a vertically integrated and highly differentiated portfolio of dermatological prescription drugs and dermatology-grade skincare products, providing comprehensive disease solutions, and maximizing the synergy among products to meet the diverse clinical needs of patients in the entire disease course.

As of the end of the Reporting Period, Dermavon had three marketed products (ILUMETRI, Hirudoid, and Aethoxysklerol), four pipeline products in clinical stages (ruxolitinib cream, MG-K10, povorcitinib, and CMS-D001), and multiple preclinical product candidates, covering major dermatological diseases. Additionally, in the field of dermatology-grade skincare products, Dermavon has two marketed product series for skin disease prevention and care, including the Heling Soothing Product Series and the Hirudoid® Azelaic Acid Skincare Series.

	Treatment			Skincare
	Topical Agents	Oral Tablets	Injections	Dermatology-Grade Skincare Products
Psoriasis		CMS-D001 (China Phase I)	ILUMETRI	
AD	ruxolitinib cream (China Phase III)	CMS-D001 (China Phase I)	MG-K10 (China Phase III)	Heling Soothing Product Series
Vitiligo	ruxolitinib cream (China NDA under review)	povorcitinib (China IND application accepted)		
Superficial phlebitis, Blunt traumata	Hirudoid			
Varicose veins			Aethoxysklerol	
Prurigo nodularis		povorcitinib (Overseas Phase III)	MG-K10 (China Phase III)	
Hidradenitis suppurativa		povorcitinib (China IND application accepted)		
Chronic spontaneous urticaria		povorcitinib (Overseas Phase II)		
Acne vulgaris				Hirudoid® Azelaic Acid Skincare Series

■ Marketed

■ Under R&D

2.Diverse and Efficient R&D Engine, Accelerating Innovation Pace

Dermavon adopts a R&D model that integrates both collaborative R&D and in-house R&D. Leveraging in-depth insights into the correlation and differentiation among the targets and mechanisms of action of different drugs, Dermavon efficiently identifies potential FIC and BIC products at different development stages. Furthermore, benefiting from its long-term dedicated efforts in dermatology field, Dermavon has accumulated extensive clinical institution and expert resources, and has fostered robust clinical development and registration capabilities, enabling efficient advancement of product development.

Dermavon possesses strong collaborative R&D capabilities, consistently following global industry technology trends to develop diversified, comprehensive dermatological disease solutions in the entire disease course. During the Reporting Period, Dermavon entered into a collaboration with Mabgeek Biotech to jointly advance the clinical development of the long-acting anti-IL-4R α monoclonal antibody MG-K10 for dermatology indications in China. Mabgeek Biotech has completed the 16-week treatment for all subjects in the Phase III clinical trial in China for the treatment of AD, and both parties are steadily progressing with the enrollment for the Phase III clinical trial in China for PN.

Furthermore, Dermavon has highly integrated in-house R&D capabilities. As of the end of the Reporting Period, its self-developed innovative drug CMS-D001 Tablets, a highly selective TYK2 inhibitor, was advancing the Phase I clinical trials in China and newly obtained IND approval for AD in July 2025. Additionally, three self-developed pipeline products are in the preclinical stage.

3. Industry-leading Commercialization Capabilities, Laying the Foundation for Large-scale Sales

Dermavon adheres to a patient-centered and market-oriented philosophy, cultivating an industry-leading sales and academic promotion team in dermatology. It has built a comprehensive, multi-level sales network covering major hospital and out-of-hospital channels, demonstrating an industry-leading position in China in terms of the coverage of dermatology departments in hospitals and the size of commercial team.

Dermavon converts R&D insights and medical evidence into academic promotion momentum, continuously enhancing team expertise. Through participation in academic conferences at all levels, Dermavon continuously strengthens the scientific recognition of products in the medical community to enhance brand influence. At the same time, Dermavon continuously advances the post-marketing clinical research and RWS to accumulate medical evidence for the products' inclusion in clinical guidelines and expert consensuses, and to provide a solid scientific basis to explore new indications and dosage regimens. As of the end of the Reporting Period, ILUMETRI, Hirudoid and ruxolitinib cream have been recommended by authoritative guidelines in multiple countries, with related clinical research results published in top domestic and foreign dermatology and pediatrics medical journals.

At the same time, leveraging the consumer attributes of dermatological prescription products and dermatology-grade skincare products, Dermavon actively explores the "New Retail" model. With brand operations as its core, it further strengthens the coverage of diverse out-of-hospital channels, including offline pharmacies and e-commerce platforms. Simultaneously, Dermavon enhances its "New Media" operational capabilities, bolsters social media promotion, expands product application scenarios, and refines its brand's omni-channel marketing model to cultivate multi-dimensional growth momentum.

IV. Ophthalmology Business

CMS Vision, the Group's specialty business subsidiary, operates independently and focuses on the development and commercialization of pharmaceutical and medical device products in ophthalmology. Centered on ophthalmology, CMS Vision is also actively expanding into the ENT (ear, nose, and throat) field, introducing and developing clinically essential innovative products worldwide, with the goal of becoming a "leading ophthalmology pharmaceutical company in China". CMS Vision's current portfolio covers ophthalmic indications such as asthenopia, glaucoma, and fundus neovascular diseases, as well as the rhinitis indication. It is committed to offering diversified solutions combining drugs and devices to continuously enrich patients' treatment options.

During the Reporting Period, CMS Vision continued to strengthen academic promotion and brand building for its marketed products, further consolidating their market position. At the same time, CMS Vision expanded its innovation pipeline with the introduction of a Class 1 innovative drug anti-IL-4R α humanized monoclonal antibody injection MG-K10 (for seasonal allergic rhinitis indication). The product is currently undergoing a Phase II clinical trial in China in collaboration with Mabgeek Biotech.

In July 2025, CMS Vision entered into a collaboration in the ophthalmology field with Jingze Pharma, an innovation-driven biopharmaceutical company specializing in two high-growth markets: assisted reproductive drugs and ophthalmic drugs. Jingze Pharma possesses clinically validated proprietary technology platforms, including complex glycoprotein process development technology, and has advanced a high-tech, commercially promising drug candidate for fundus neovascular diseases to late-stage clinical trials. Leveraging Jingze Pharma's strong R&D capabilities in ophthalmology and the Group's robust clinical development and commercialization strengths, the two parties will collaborate to achieve complementary advantages and high-efficiency synergies, to accelerate the release of innovation value.

1. Major Marketed Products

During the Reporting Period, CMS Vision had two major marketed products:

Exclusive Drug: Augentropfen Stulln Mono Eye Drops

The representative for the treatment of asthenopia, and the safe and convenient treatment option for senile macular degeneration. Its active ingredient, Esculin and Digitalisglycosides, has been included in several authoritative guidelines, such as the "Chinese Expert Consensus on the Diagnosis and Treatment of Asthenopia (2024)" and "Chinese Expert Consensus on the Perioperative Medication in Laser Corneal Refractive Surgery (2024)". CMS Vision has continued to conduct precise academic promotion within ophthalmic subspecialties, supported by its core advantages and robust medical evidence.

Innovative Medical Device: EyeOP1 Glaucoma Treatment Device

Applying high-focused ultrasound technology, this device offers a safe and effective innovative treatment for glaucoma utilizing a non-invasive procedure with precise targeting and convenient operations. Through multi-level, wide-reaching academic initiatives, CMS Vision has further reinforced its brand positioning as a "non-incisional, minimally invasive" solution, while promoting the advancement of treatment concepts and enhancing clinical awareness and adoption of the innovative Ultrasonic Cyclo Plasticity (UCP).

2. Major Pipeline Products

During the Reporting Period, CMS Vision newly obtained a pipeline product—MG-K10, an anti-IL-4R α humanized monoclonal antibody injection for the treatment of seasonal allergic rhinitis. MG-K10 simultaneously blocks the signaling of key type 2 inflammatory cytokines IL-4 and IL-13. Following Fc mutation, it allows long dosing interval owing to its prolonged half-life, and it is expected to be the first long-acting anti-IL-4R α monoclonal antibody marketed in China (one dose every four weeks). As of the end of the Reporting Period, the China Phase II clinical trial for the seasonal allergic rhinitis indication was progressing steadily.

V. International Business

On 15 July 2025, the Group successfully completed its secondary listing on the SGX-ST by way of introduction. This secondary listing is expected to attract Asia-Pacific-focused funds and Southeast Asian local capital, optimize the Group's shareholder structure, enhance its global recognition and market position, and further support the establishment of a synergistic Asia-Pacific platform. It will close the loop in the Group's "R&D – Manufacturing – Commercialization" value chain under its "industrial internationalization" strategy, unlock incremental value in emerging markets, and foster a multi-regional growth pattern.

Emerging markets such as Southeast Asia and the Middle East are experiencing a critical phase of accelerated pharmaceutical demand, driven by large population bases, expanding middle-class segments, aging demographics, improving healthcare infrastructure, and increasing chronic disease burden. These regions have become new growth engines for the global pharmaceutical industry. With over three decades of development, CMS has built a rich portfolio of differentiated products and mature commercialization capabilities in the China market. These advantages and capabilities are now spilling over into emerging markets, driving the development of a full pharmaceutical value chain in these regions. Leveraging professional teams with deep local market experience, the Group is well-positioned to seize mid- to long-term structural opportunities and significantly enhance drug accessibility in these regions.

Since 2022, CMS has advanced its “industrial internationalization” strategy by establishing Singapore as its hub for emerging markets in the Asia-Pacific region. The Group has built a fully integrated ecosystem comprising CMS R&D (research), PharmaGend (manufacturing), and Rxilient (commercialization), enabling comprehensive development across Asia-Pacific markets.

1. Internationalization of Commercialization

Rxilient is a platform for the introduction, development, and commercialization of pharmaceutical products, operated by a professional and experienced local team. Headquartered in Singapore as the Group’s base for emerging market business, Rxilient has established subsidiaries or offices in Hong Kong, Taiwan Region, Malaysia, Vietnam, the Philippines, Indonesia, Thailand, and the United Arab Emirates.

During the Reporting Period, Rxilient actively advanced product introduction and registration. It obtained an exclusive right to develop, register, manufacture, import, export and commercialize ZUNVEYL, an improved new drug, in Asia (excluding Mainland China, Japan, and the Middle East region) and other designated territories. It also formally submitted the registration application for Tildrakizumab Injection in Taiwan Region. In commercialization, Rxilient made notable progress by engaging with Hong Kong’s Hospital Authority (HA) and submitting a proposal based on local clinical practice and health-economics data, resulting in the successful inclusion of Sucroferic Oxyhydroxide Chewable Tablets into the “Special Drug” category on the HA Drug Formulary.

As of the end of the Reporting Period, Rxilient has cumulatively submitted nearly 20 registration applications for pharmaceutical products and medical devices across Southeast Asia, the Middle East, Hong Kong, Macau, and Taiwan Region, covering therapeutic fields such as dermatology, ophthalmology, oncology, autoimmune, and central nervous system. Among these, core product ruxolitinib cream (vitiligo indication) has been approved for marketing in Macau and Hong Kong, and its registration applications have been submitted in Singapore and Taiwan Region. Intravenous Toripalimab (the first China-originated anti-PD-1 monoclonal antibody drug that has been approved by the China NMPA and the U.S. FDA) has been submitted for registration in Malaysia, the Philippines, Indonesia, Thailand, and Vietnam. Tildrakizumab Injection and Sucroferic Oxyhydroxide Chewable Tablets have been approved for marketing in Hong Kong.

2. Internationalization of Manufacturing

PharmaGend, an associate company of the Group based in Singapore, is an international one-stop CDMO platform. The Group holds a 45.0% equity interest in PharmaGend through several subsidiaries. As of the end of the Reporting Period, PharmaGend had a manufacturing site of 30,000 square meters. PharmaGend’s current oral solid dosage (OSD) production lines, which mainly produce tablets and capsules and have an annual capacity of 1 billion units, have obtained a drug manufacturing license issued by the Health Sciences Authority (HSA) of Singapore, Current Good Manufacturing Practice (cGMP) certification from the U.S. FDA, and have passed audits by Swiss Qualified Persons (QPs), demonstrating high-standard pharmaceutical manufacturing capabilities for global distribution. Meanwhile, capacity expansion is progressing smoothly, including the planned construction of new production lines for nasal sprays, creams, and injectables, as well as a packaging center.

Future Development

CMS will stay unwaveringly committed to the “New CMS, New Ascent” strategic resolve, focusing on the three core strategies of product innovation, commercial model reform, and international expansion, to further broaden and deepen the Group’s development path and accelerate the formation of a sustainable new growth engine.

We will rely on the three-dimensional innovation system—overseas licensing, domestic collaboration, and in-house R&D—to continuously expand our product pipeline. We will focus on addressing unmet clinical needs, align with the support of reimbursement policies for high-value innovations, and build a more competitive and accessible product portfolio. The power of innovative products will serve as a long-term driver that enables the Group to grow sustainably across market cycles.

We remain committed to a specialty-focused strategy, with deep cultivation in our advantageous therapeutic areas including cardio-cerebrovascular, central nervous system, gastroenterology, skin health, and ophthalmology. Meanwhile, we continue to empower the independent development of specialty businesses such as skin health and ophthalmology, aiming to build leading players in their respective segments and unlock further value creation potentials. In addition, the Group proactively anticipates evolving trends in healthcare payment mechanisms and consumer behavior, and is actively expanding into diversified models such as new retail, new media, and consumer healthcare. We are building an integrated commercial ecosystem that connects in-hospital and out-of-hospital channels, and enables interaction between online and offline promotion. By accelerating our presence in the consumer healthcare market, we are enhancing terminal reach and market penetration, and unlocking incremental growth potential from the integration of pharmaceuticals and consumer markets.

In terms of international expansion, we are accelerating innovation through a dual-hub model centered on China and Singapore, leveraging dual-track cycles to unlock global growth opportunities. This reflects a strategic elevation toward global allocation of industrial resources, positioning CMS to lead a new paradigm for Chinese pharmaceutical companies expanding overseas, and to build a replicable, scalable, and sustainable development model for internationalized pharmaceutical operations.

CMS will stay true to its original aspiration for innovation and maintain its spirit of progress, working hand-in-hand with global partners to co-create a sustainable pharmaceutical ecosystem and jointly embark on an advanced journey toward healthy and sustainable development.

Financial Review

Turnover

Turnover increased by 10.8% to RMB4,002.0 million for the six months ended 30 June 2025 from RMB3,611.1 million for the six months ended 30 June 2024; in the case that all medicines were directly sold by the Group, turnover increased by 8.9% to RMB4,669.6 million for the six months ended 30 June 2025 from RMB4,287.5 million for the six months ended 30 June 2024, mainly due to a continuing growth in sales of innovative and exclusive/branded products, couple with the cessation of the material adverse impact from the National VBP on three products.

Gross Profit and Gross Profit Margin

Gross profit increased by 7.2% to RMB2,891.9 million for the six months ended 30 June 2025 from RMB2,696.5 million for the six months ended 30 June 2024; in the case that all medicines were directly sold by the Group, gross profit increased by 7.2% to RMB2,881.7 million for the six months ended 30 June 2025 from RMB2,686.9 million for the six months ended 30 June 2024, primarily reflecting an increase in turnover. For the six months ended 30 June 2025, gross profit margin was 72.3%, representing a decrease of 2.4 percentage points from 74.7% for the six months ended 30 June 2024; in the case that all medicines were directly sold by the Group, gross profit margin decreased by 1.0 percentage point to 61.7% for the six months ended 30 June 2025 from 62.7% for the six months ended 30 June 2024, mainly due to a decrease in selling prices of three products resulted from the impact of implementation of the National VBP.

Selling Expenses

Selling expenses increased by 1.7% to RMB1,424.5 million for the six months ended 30 June 2025 from RMB1,400.5 million for the six months ended 30 June 2024. Selling expenses as a percentage of turnover was 35.6% for the six months ended 30 June 2025, representing a decrease of 3.2 percentage points from 38.8% for the six months ended 30 June 2024. In the case that all medicines were directly sold by the Group, selling expenses as a percentage of turnover decreased by 2.1 percentage points to 30.3% for the six months ended 30 June 2025 from 32.4% for the six months ended 30 June 2024, primarily reflecting an economy of scale generated from the brand and the increase in turnover.

Administrative Expenses

Administrative expenses increased by 19.2% to RMB430.8 million for the six months ended 30 June 2025 from RMB361.5 million for the six months ended 30 June 2024. Administrative expenses as a percentage of turnover for the six months ended 30 June 2025 was 10.8%, representing an increase of 0.8 percentage point from 10.0% for the six months ended 30 June 2024. In the case that all medicines were directly sold by the Group, administrative expenses as a percentage of turnover increased by 0.8 percentage point to 9.2% for the six months ended 30 June 2025 from 8.4% for the six months ended 30 June 2024, mainly due to increases in human costs and listing related expenses.

Research and Development Expenditures

The Group's research and development expenditures included investments for the continuous expansion of innovative product pipelines, expenditures on research and development and clinical trial of new products, salaries and related expenses of staff who were engaged in the aforesaid affairs. Research and development expenditures included the expensed research and development expenditures (i.e. research and development expenses) and capital payments (including payments for clinical trial and acquisition of product rights of new products and equity investments in these companies).

Total research and development expenditures decreased by 8.2% to RMB571.4 million for the six months ended 30 June 2025 from RMB622.2 million for the six months ended 30 June 2024. Total research and development expenditures as a percentage of turnover for the six months ended 30 June 2025 was 14.3%, representing a decrease of 2.9 percentage points from 17.2% for the six months ended 30 June 2024. In the case that all medicines were directly sold by the Group, total research and development expenditures as a percentage of turnover decreased by 2.3 percentage points to 12.2% for the six months ended 30 June 2025 from 14.5% for the six months ended 30 June 2024, mainly due to a decrease in payments for acquisition of product rights.

Research and development expenses increased by 91.8% to RMB202.5 million for the six months ended 30 June 2025 from RMB105.6 million for the six months ended 30 June 2024. Research and development expenses as a percentage of turnover for the six months ended 30 June 2025 was 5.1%, representing an increase of 2.2 percentage points from 2.9% for the six months ended 30 June 2024. In the case that all medicines were directly sold by the Group, research and development expenses as a percentage of turnover increased by 1.8 percentage points to 4.3% for the six months ended 30 June 2025 from 2.5% for the six months ended 30 June 2024, mainly due to an increase in research and development expenses of self-developed products.

Capital payments (set out in the table below) decreased by 28.6% to RMB368.9 million for the six months ended 30 June 2025 from RMB516.6 million for the six months ended 30 June 2024. Such capital payments as a percentage of turnover for the six months ended 30 June 2025 was 9.2%, representing a decrease of 5.1 percentage points from 14.3% for the six months ended 30 June 2024. In the case that all medicines were directly sold by the Group, such capital payments as a percentage of turnover decreased by 4.1 percentage points to 7.9% for the six months ended 30 June 2025 from 12.0% for the six months ended 30 June 2024.

	For the six months ended 30 June	
	2025	2024
	RMB'000	RMB'000
Payment for acquisition of equity investments in research and development companies	143,760	60,033
Payment for acquisition and development of product rights	225,113	456,605
	<u>368,873</u>	<u>516,638</u>

Other Income

Other income decreased by 45.2% to RMB79.2 million for the six months ended 30 June 2025 from RMB144.5 million for the six months ended 30 June 2024, mainly due to decreases in government subsidies and interest income resulting from a decrease in interest rates of deposits.

Other Gains and Losses

Other gains and losses increased by 410.4% to a gain of RMB76.7 million for the six months ended 30 June 2025 from a loss of RMB24.7 million for the six months ended 30 June 2024, mainly due to an increase in equity investment income.

Share of Result of Associates/a Joint Venture

Share of result of associates/a joint venture decreased by 21.0% to RMB165.4 million for the six months ended 30 June 2025 from RMB209.3 million for the six months ended 30 June 2024, mainly reflecting a decrease in profit of associates.

Finance Costs

Finance costs decreased by 47.9% to RMB11.3 million for the six months ended 30 June 2025 from RMB21.6 million for the six months ended 30 June 2024, mainly due to decreases in bank borrowings used and interest rates.

Income Tax Expense

Income tax expense decreased by 8.8% to RMB212.6 million for the six months ended 30 June 2025 from RMB232.9 million for the six months ended 30 June 2024, mainly due to a withholding tax on intercompany dividend distribution paid during the six months ended 30 June 2024.

Profit for the Period

Profit for the period increased by 3.1% to RMB931.5 million for the six months ended 30 June 2025 from RMB903.4 million for the six months ended 30 June 2024, mainly due to increases in turnover and equity investment income.

Inventories

Inventories increased by 3.1% to RMB792.0 million as at 30 June 2025 from RMB768.1 million as at 31 December 2024. Average inventory turnover days increased by 1 day to 129 days for the six months ended 30 June 2025 from 128 days for the six months ended 30 June 2024.

Trade Receivables

Trade receivables increased by 18.0% to RMB1,442.1 million as at 30 June 2025 from RMB1,222.5 million as at 31 December 2024. Average trade receivables turnover days decreased by 1 day to 79 days for the six months ended 30 June 2025 from 80 days for the six months ended 30 June 2024.

Trade Payables

Trade payables decreased by 3.6% to RMB137.3 million as at 30 June 2025 from RMB142.4 million as at 31 December 2024. Average trade payables days decreased by 9 days to 23 days for the six months ended 30 June 2025 from 32 days for the six months ended 30 June 2024, primarily reflecting the difference in time points of settlement with suppliers.

Liquidity, Financial Resources, Capital Structure and Gearing Ratio

As at 30 June 2025, the Group's bank balances and cash amounted to RMB3,454.1 million while readily realizable bank acceptance bills amounted to RMB178.6 million. As at 31 December 2024, our bank balances and cash amounted to RMB3,706.5 million while readily realizable bank acceptance bills amounted to RMB198.8 million.

The Group had bank borrowings of RMB715.0 million (31 December 2024: RMB831.3 million) as at 30 June 2025. The weighted average interest rate of loans was 2.3% (six months ended 30 June 2024: 3.3%) per annum. All the loans were due within one year and then classified as current liabilities.

As at 30 June 2025 and 31 December 2024, the Group had a gearing ratio (being the bank borrowings of the Group divided by the total assets of the Group) of approximately 3.8% and 4.6%, respectively.

The Group's liquidity requirements will be satisfied by a combination of cash flow generated from operating activities, long-term bank loans and other financing means which the Company may from time to time consider appropriate.

Exposure to Fluctuations in Exchange Rates and Interest Rates

The Group is mainly exposed to currency risk of the US\$, EUR and HK\$. The conversion of RMB into foreign currencies is subject to the rules and regulations of foreign exchange control promulgated by the PRC government. Any significant exchange rate fluctuations of foreign currencies against RMB may have a financial impact on the Group. The Group closely monitors exchange rate fluctuations and reviews the foreign currency risk management strategy from time to time, and where appropriate, the management will consider hedging its foreign currency exposure.

The Group will closely monitor movements of interest rates and foreign currencies market so as to mitigate the expected risk on interest rates and foreign currencies.

Pledge of Assets

As at 30 June 2025, the Group had no pledge of assets.

Contingent Liabilities

As at 30 June 2025, the Group had no material contingent liabilities.

Acquisitions and Disposals of Subsidiaries, Associates and Joint Ventures

There has been no significant acquisition or disposal of subsidiaries, associates or joint ventures by the Group during the six months ended 30 June 2025.

OTHER INFORMATION

Share Award Scheme

The CMS Share Award Scheme was adopted on 17 January 2024 by a resolution of the Board. Details regarding grants to be satisfied by existing shares will be disclosed in the annual report ending 31 December 2025 according to the Listing Rules' requirements.

Share Option Scheme

As of the end of the Reporting Period, the Company did not have any share option scheme.

Interim Dividend

The Board has resolved to pay an interim dividend of RMB0.1555 (equivalent to HKD0.171 and SGD0.028) per ordinary share of the Company for the six months ended 30 June 2025 to the shareholders ("Shareholders") whose names appear on the register of members of the Company after market closes on Tuesday, 2 September 2025 (the "Record Date"). Payment of such interim dividend is expected to be made to the Shareholders on about Tuesday, 9 September 2025. For the purpose of determination of the Shareholders registered under the Company's register of members in Hong Kong and register of members in Singapore for receiving the interim dividend in Hong Kong dollars or Singapore dollars respectively, any removal of the Shares between the Company's register of members in Hong Kong and register of members in Singapore has to be made by the Shareholders no later than 4:30 p.m. (both Hong Kong and Singapore times) on Tuesday, 19 August 2025.

Closure of Register of Members

For Hong Kong Shareholders

The register of members of the Company will be closed on Tuesday, 2 September 2025, on which the registration of transfer of shares of the Company will be suspended. To qualify for the interim dividend, all transfer forms of Shares accompanied by the relevant share certificates must be lodged with the Company's branch share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17/F, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong, for registration no later than 4:30 p.m. (Hong Kong time) on Monday, 1 September 2025. Interim dividend will be paid in Hong Kong dollars to Hong Kong Shareholders.

For Singapore Shareholders

To qualify for the interim dividend, all transfer documents accompanied by the relevant share certificates must be lodged with the Company's Singapore share transfer agent, In.Corp Corporate Services Pte. Ltd. at 36 Robinson Road, #20-01 City House, Singapore 068877 for registration no later than 5:00 p.m. (Singapore time) on Tuesday, 2 September 2025. Interim dividend will be paid in Singapore dollars to Singapore Shareholders.

Directors' and Chief Executive's Interests and Short Positions in Shares, Underlying Shares and Debentures of the Company and Its Associated Corporations

As of 30 June 2025, the interests or short positions of the Directors and Chief Executive in the shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the Securities and Futures Ordinance (the "SFO")) as recorded in the register required to be kept by the Company pursuant to section 352 of the SFO, or as otherwise notified to the Company and the SEHK, pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers (the "Model Code") as set out in Appendix C3 of the Listing Rules were as follows:

Name of Directors	Nature of Interest	Class of Shares and Total Number of Shares /Underlying Shares Held (Note 1)	Approximate Percentage of shareholdings as of 30 June 2025
(a) The Company			
Mr. Lam Kong	Interest in controlled corporation	1,167,564,000 (L) (Note 2)	47.86%
Mr. Chen Hongbing	Beneficial owner	17,038,225 (L)	0.70%
	Interest in controlled corporation	50,225,000 (L) (Note 3)	2.06%
Ms. Chen Yanling	Beneficial owner	7,246,250 (L)	0.30%
(b) Associated Corporation – Dermavon Holdings Limited			
Mr. Lam Kong	Beneficial owner	97 (L) (Note 4)	0.89%
Ms. Chen Yanling	Beneficial owner	104 (L) (Note 5)	0.95%

Notes:

1. The letter "L" denotes long positions in the Shares.
2. These Shares are held by Mr. Lam Kong through Treasure Sea Limited, a company wholly owned by him.
3. These Shares are held by Mr. Chen Hongbing through Viewell Limited, a company wholly owned by him.
4. Mr. Lam Kong is entitled to 97 unvested shares underlying the awards granted to Mr. Lam under the share award scheme of Dermavon Holdings Limited.
5. Ms. Chen Yanling is entitled to 104 unvested shares underlying the restricted share units granted to Ms. Chen under the share incentive scheme of Dermavon Holdings Limited.

Save as disclosed above, as of 30 June 2025, none of the Directors and Chief Executive of the Company had any interests or short positions in the shares, underlying shares or debentures of the Company or its associated corporations (within the meaning in Part XV of the SFO), which were required to be and are recorded in the register required to be kept by the Company pursuant to section 352 of the SFO, or which were required to be notified to the Company and the SEHK, pursuant to the Model Code.

Directors' Right to Acquire Shares or Debentures

At no time during the Reporting Period were rights to acquire benefits by means of the acquisition of shares in or debentures of the Company granted to any Director or their respective spouses or minor children, or were any such rights exercised by them; nor was the Company or any of its subsidiaries a party to any arrangements to enable the Directors, their respective spouses or minor children to acquire such rights in any other body corporate.

Substantial Shareholders' Interests and Short Positions in Shares, Underlying Shares and Debentures of the Company and Its Associated Corporations

Saved as disclosed above, as of 30 June 2025, the Directors were not aware of any other person (other than the Directors or the Chief Executive of the Company) who held interests and short positions in the shares or underlying shares or debentures of the Company which would have to be disclosed to the Company and the Stock Exchange pursuant to Divisions 2 and 3 of Part XV of the SFO or were recorded in the register required to be kept by the Company pursuant to Section 336 of the SFO.

Purchase, Sale or Redemption of the Company's Listed Securities

None of the Company or any of its subsidiaries has purchased, sold or redeemed any of the listed securities (including treasury shares (as defined under the Listing Rules)) of the Company during the Reporting Period.

Employees

As of 30 June 2025, the Group had a total of 6,095 employees. To meet the talent development needs of the Group, the Group continuously optimize the Group's strategy, organizational structure, improve the Group's performance management and salary incentive system, etc., further stimulate organizational vitality and improve organizational operation efficiency, enabling the Group's human resource management to fully match with the Group's development strategy. The Group provides employees with competitive remuneration packages, including medium- and long-term equity incentive schemes, salaries, bonuses, insurance and benefits, which are based on employees' performance and are measured against specific objective criteria. Additionally, the Group is committed to providing equal opportunities to all employees in all respects and has made efforts in continuing education and training programs for employees, such as orientation programs for new employees, regulation-related trainings and job skills trainings, to continuously enhance employees' knowledge, skills and teamwork spirit.

Audit Committee

The Company established an Audit Committee in 2007. The Audit Committee currently comprises three independent non-executive Directors, and is chaired by Mr. Fung Ching Simon, with Mr. Leung Chong Shun and Ms. Luo Laura Ying as Committee members.

The primary duties of the Audit Committee are to provide the Directors with an independent review of the effectiveness of the financial reporting process, internal control and risk management system of the Company, to oversee the audit process and to perform other duties and responsibilities as assigned by the Directors. The Audit Committee also oversees the Company's appointment of external auditors.

The Company's interim result announcement and interim report for the six months ended 30 June 2025 have been reviewed by the Audit Committee of the Company and approved by the Board with recommendation of the Audit Committee.

Changes in Director's Information

Pursuant to Rule 13.51B (1) of the Listing Rules, during the Reporting Period and up to the Latest Practicable Date (18 August 2025) of this Interim Report, changes in the information of the Directors are listed as below:

Ms. Luo Laura Ying resigned from the positions of investment director at GL China Equity HK Management Limited in June 2025.

Mr. Chen Hongbing resigned as a non-executive Director of the Company with effect from 18 August 2025.

Corporate Governance Practices

During the Reporting Period, the Company has complied with the applicable principles and code provisions of the Corporate Governance Code (the “CG Code”) as set out in Appendix C1 to the Listing Rules, except for a deviation from the Code Provision C.2.1 in respect of the roles of Chairman and Chief Executive which shall not be performed by the same individual.

Mr. Lam Kong has been both the Chairman and Chief Executive of the Company and his responsibilities are clearly established and set out in writing and approved by the Board. Given the Group’s current stage of development, the Board considers that vesting the roles of Chairman and Chief Executive in the same person facilitates the execution of the Group’s business strategies and maximizes effectiveness of its operations. The Board shall nevertheless review the Group’s management structure from time to time and shall consider any appropriate adjustments should new circumstances arise.

The Company makes available to the Directors monthly updates of the Company, in order to keep the Directors informed of the Company’s latest performance and operations. In addition, the Directors also receive regular updates from time to time on changes and developments of the relevant legislation and regulatory environments.

All Directors participate in continuous professional development to develop and refresh their knowledge and skills to ensure that their advice to the Board remains effective and relevant. The Company keeps records of the training received by Directors.

Directors’ Securities Transactions

The Company has adopted the Written Guidelines for Securities Transactions by Directors and Relevant Employees (the “Written Guidelines”) on no less exacting terms than the Model Code as the code of conduct for Directors’ securities transactions. Having made specific inquiries in relation to the compliance with the Written Guidelines for securities transactions by Directors, the Company confirmed that all the Directors have complied with the relevant standards for securities transactions by Directors set out in the Written Guidelines during the Reporting Period. The Written Guidelines also apply to other specified senior management of the Company.

Employees who are likely to be in possession of unpublished price-sensitive information about the Company are also subject to compliance with the Written Guidelines. No incident of non-compliance with the Written Guidelines by such employees was noted by the Company in the Reporting Period.

Disclosure of Information

The Interim Report for the Reporting Period will be duly dispatched to shareholders of the Company and published on websites of the SEHK (www.hkexnews.hk), the SGX-ST (www.sgx.com) and the Company (www.cms.net.cn).

CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

FOR THE SIX MONTHS ENDED 30 JUNE 2025

		Six months ended 30 June	
	NOTES	2025	2024
		RMB'000	RMB'000
		(unaudited)	(unaudited)
Turnover	3	4,001,980	3,611,069
Cost of goods sold		(1,110,068)	(914,569)
Gross profit		2,891,912	2,696,500
Other income		79,155	144,457
Other gains and losses		76,658	(24,697)
Selling expenses		(1,424,465)	(1,400,459)
Administrative expenses		(430,817)	(361,505)
Research and development expenses		(202,489)	(105,575)
Finance costs		(11,277)	(21,649)
Share of results of associates		164,619	209,596
Share of results of a joint venture		749	(332)
Profit before tax		1,144,045	1,136,336
Income tax expense	4	(212,552)	(232,934)
Profit for the period	5	931,493	903,402
<i>Items that may be reclassified subsequently to profit or loss:</i>			
Share of other comprehensive (expense) income of associates		(1,845)	2,512
Exchange differences arising on translation of foreign operations		(1,082)	1,204
Exchange differences arising on translation of interest in associates		25,455	(6,176)
<i>Items that will not be reclassified to profit or loss:</i>			
Fair value gain (loss) on equity instrument at fair value through other comprehensive income		633	(81,443)
Other comprehensive income (expense) for the period, net of income tax		23,161	(83,903)
Total comprehensive income for the period		954,654	819,499
Profit (loss) for the period attributable to:			
Owners of the Company		941,178	910,426
Non-controlling interests		(9,685)	(7,024)
		931,493	903,402
Total comprehensive income (expense) for the period attributable to:			
Owners of the Company		964,339	826,523
Non-controlling interests		(9,685)	(7,024)
		954,654	819,499
Earnings per share	7	RMB	RMB
Basic		0.3892	0.3734

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

AT 30 JUNE 2025

	NOTES	30 June 2025 RMB'000 (unaudited)	31 December 2024 RMB'000 (audited)
Non-current assets			
Property, plant and equipment	8	360,759	375,893
Right-of-use assets		74,821	72,197
Interest in associates	9	3,584,523	3,389,827
Interest in a joint venture		169,551	181,804
Intangible assets		2,289,022	2,301,346
Goodwill		1,547,903	1,547,903
Equity instruments at fair value through other comprehensive income		130,416	129,783
Deposits paid for acquisition of intangible assets		1,318,655	1,189,256
Amount due from an associate	11	30,000	30,000
Deferred tax assets		61,343	52,693
Loan receivable		80,641	72,227
		<u>9,647,634</u>	<u>9,342,929</u>
Current assets			
Inventories		791,990	768,139
Financial asset at fair value through profit or loss		2,514,103	2,160,097
Trade and other receivables and prepayments	10	2,048,718	1,780,483
Tax recoverable		5,553	5,553
Amount due from associates	11	475,014	284,088
Bank balances and cash		3,454,072	3,706,501
		<u>9,289,450</u>	<u>8,704,861</u>
Current liabilities			
Trade and other payables	12	638,720	484,797
Lease liabilities		13,278	16,933
Contract liabilities		13,814	16,610
Bank borrowings	13	715,000	831,300
Tax liabilities		227,424	166,423
		<u>1,608,236</u>	<u>1,516,063</u>
Net current assets		<u>7,681,214</u>	<u>7,188,798</u>
Total assets less current liabilities		<u>17,328,848</u>	<u>16,531,727</u>

CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

(CONTINUED)

AT 30 JUNE 2025

	NOTE	30 June 2025 RMB'000 (unaudited)	31 December 2024 RMB'000 (audited)
Capital and reserves			
Share capital	14	83,564	83,564
Reserves		16,935,387	16,227,905
Equity attributable to owners of the Company		17,018,951	16,311,469
Non-controlling interests		146,766	91,639
		17,165,717	16,403,108
Non-current liabilities			
Deferred tax liabilities		143,811	116,109
Lease liabilities		19,320	12,510
		163,131	128,619
		17,328,848	16,531,727

The condensed consolidated financial statements on pages 33 to 48 were approved and authorised for issue by the Board of Directors on 18 August 2025 and are signed on its behalf by:

LAM Kong
DIRECTOR

CHEN Yanling
DIRECTOR

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE SIX MONTHS ENDED 30 JUNE 2025

	Attributable to owners of the Company										Attributable to non-controlling interests	Total
	Share Capital RMB'000	Share premium RMB'000	Capital reserve RMB'000	Surplus reserve fund RMB'000	Translation reserve RMB'000	Investments revaluation reserve RMB'000	Accumulated profits RMB'000	Dividend reserve RMB'000	Treasury stock RMB'000	Sub-total RMB'000		
Balance at 1 January 2025 (audited)	83,564	2,025,601	19,545	438,872	65,191	(406,066)	13,959,009	283,700	(157,947)	16,311,469	91,639	16,403,108
Profit (loss) for the period	-	-	-	-	-	-	941,178	-	-	941,178	(9,685)	931,493
Other comprehensive income for the period	-	-	-	-	22,528	633	-	-	-	23,161	-	23,161
Total comprehensive income (expense) for the period	-	-	-	-	22,528	633	941,178	-	-	964,339	(9,685)	954,654
Recognition of equity-settled share-based payments(note 14)	-	24	-	-	-	-	-	-	27,286	27,310	-	27,310
Capital contribution from non-controlling interests	-	-	-	-	-	-	-	-	-	-	64,812	64,812
Dividends paid (note 6)	-	-	-	-	-	-	(467)	(283,700)	-	(284,167)	-	(284,167)
Dividends proposed (note 6)	-	-	-	-	-	-	(376,388)	376,388	-	-	-	-
Transfer of reserves	-	-	-	793	-	-	(793)	-	-	-	-	-
Balance at 30 June 2025 (unaudited)	83,564	2,025,625	19,545	439,665	87,719	(405,433)	14,522,539	376,388	(130,661)	17,018,951	146,766	17,165,717

	Attributable to owners of the Company										Attributable to non-controlling interests	Total
	Share Capital RMB'000	Share premium RMB'000	Capital reserve RMB'000	Surplus reserve fund RMB'000	Translation reserve RMB'000	Investments revaluation reserve RMB'000	Accumulated profits RMB'000	Dividend reserve RMB'000	Treasury stock RMB'000	Sub-total RMB'000		
Balance at 1 January 2024 (audited)	83,991	2,105,621	19,545	425,635	65,052	(371,956)	13,000,329	191,991	-	15,520,208	36,199	15,556,407
Profit (loss) for the period	-	-	-	-	-	-	910,426	-	-	910,426	(7,024)	903,402
Other comprehensive expense for the period	-	-	-	-	(2,460)	(81,443)	-	-	-	(83,903)	-	(83,903)
Total comprehensive (expense) income for the period	-	-	-	-	(2,460)	(81,443)	910,426	-	-	826,523	(7,024)	819,499
Repurchase and cancellation of ordinary shares	(427)	(80,020)	-	-	-	-	-	-	-	(80,447)	-	(80,447)
Repurchased but not cancelled ordinary shares	-	-	-	-	-	-	-	-	(157,947)	(157,947)	-	(157,947)
Capital contribution from non-controlling interests	-	-	-	-	-	-	-	-	-	-	26,475	26,475
Dividends paid (note 6)	-	-	-	-	-	-	-	(191,991)	-	(191,991)	-	(191,991)
Dividends proposed (note 6)	-	-	-	-	-	-	(364,171)	364,171	-	-	-	-
Transfer of reserves	-	-	-	3,881	-	-	(3,881)	-	-	-	-	-
Balance at 30 June 2024 (unaudited)	83,564	2,025,601	19,545	429,516	62,592	(453,399)	13,542,703	364,171	(157,947)	15,916,346	55,650	15,971,996

CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

FOR THE SIX MONTHS ENDED 30 JUNE 2025

	NOTES	Six months ended 30 June	
		2025 RMB'000 (unaudited)	2024 RMB'000 (unaudited)
Net cash from operating activities		556,838	872,866
Net cash used in investing activities			
Purchase of property, plant and equipment	8	(7,298)	(4,329)
Payments for acquisitions of financial assets at fair value through profit or loss		(277,441)	(296,314)
Deposits for acquisition of intangible assets		(225,113)	(456,605)
Interest received		38,737	58,175
Dividend received from associates		132,202	68,260
Dividend received from financial assets at fair value through profit or loss		6,943	-
Capital injection to associates		(125,667)	(2,906)
		(457,637)	(633,719)
Net cash used in financing activities			
Interest paid		(11,317)	(29,474)
Dividends paid	6	(284,167)	(191,991)
Payment of deferred consideration payables		-	(1,000)
Payment of lease liabilities		(8,981)	(7,857)
New bank borrowings raised		305,700	422,000
Repayment of bank borrowings		(422,000)	(590,000)
Payment on repurchase of shares		-	(238,394)
Capital contribution from non-controlling interests		64,812	2,794
		(355,953)	(633,922)
Net decrease in cash and cash equivalents		(256,752)	(394,775)
Cash and cash equivalent at beginning of the period		3,706,501	4,311,058
Effect of exchange rate changes on the balance of cash held in foreign currencies		4,323	(1,911)
Cash and cash equivalent at end of the period, represented by bank balances and cash		3,454,072	3,914,372

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

FOR THE SIX MONTHS ENDED 30 JUNE 2025

1. BASIS OF PREPARATION

The condensed consolidated financial statements have been prepared in accordance with International Accounting Standard 34 *Interim Financial Reporting* issued by the International Accounting Standards Board ("IASB") as well as with the applicable disclosure requirements of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited.

2. PRINCIPAL ACCOUNTING POLICIES

The condensed consolidated financial statements have been prepared on the historical cost basis except for certain financial instruments, which are measured at fair values, as appropriate.

Except as described below, the accounting policies and methods of computation used in the condensed consolidated financial statements for the six months ended 30 June 2025 are the same as those followed in the preparation of the Group's annual financial statements for the year ended 31 December 2024.

In the current interim period, the Group has applied, for the first time, certain revised IFRS Accounting Standards issued by the IASB that are mandatorily effective for the Group's annual period beginning on 1 January 2025 for the preparation of the Group's condensed consolidated financial statements. The application of revised IFRS Accounting Standards in the current interim period has had no material effect on the amounts reported in these condensed consolidated financial statements and/or disclosures set out in these condensed consolidated financial statements.

3. TURNOVER AND SEGMENT INFORMATION

Turnover

The Group mainly sells pharmaceutical products to distributors throughout the PRC and provides promotion services to certain pharmaceutical manufacturers.

For sales of pharmaceutical products to customers, revenue is recognised at a point in time when control of the pharmaceutical products is passed to customers, i.e. when the products are delivered and titles have passed to customers upon receipt by customers.

For provision of promotion services to customers, revenue is recognised at a point in time when the Group satisfies its obligation to arrange for the pharmaceutical products to be provided by suppliers to distributors.

The following is an analysis of the Group's revenue from its major products and services:

	Six months ended 30 June	
	2025	2024
	RMB'000	RMB'000
Sales of pharmaceutical products	3,088,802	2,685,638
Promotion income	913,178	925,431
	<u>4,001,980</u>	<u>3,611,069</u>

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(CONTINUED)

FOR THE SIX MONTHS ENDED 30 JUNE 2025

The sale and promotion income of the Group are generated from external customers, which are primarily located in the PRC.

Segment information

The Group determines its operating segments based on the internal reports reviewed by the chief operating decision maker, the Executive Directors of the Company that are used for resources allocation and assessment of segment performance.

During the Reporting Period, the Group reorganised its internal reporting structure which resulted in changes to the composition of its reportable segments. The number of its reportable operating segment was changed to two segments, i.e. (i) integrated pharmaceuticals portfolio (the “Integrated Business”) and (ii) skin diseases related business (the “Skin Health Business”), from one segment that was research and development, promotion, sales and manufacturing of pharmaceutical products. Prior year segment disclosures have been represented to conform with the current Reporting Period’s presentation.

The revenue and performance of reportable operating segments of the group are analyzed below:

For the six months ended 30 June 2025

	<u>Integrated Business</u>	<u>Skin Health Business</u>	<u>Elimination</u>	<u>Total</u>
	<u>RMB’000</u>	<u>RMB’000</u>	<u>RMB’000</u>	<u>RMB’000</u>
External revenue	3,528,576	473,404	-	4,001,980
Inter-segment revenue	18,953	24,624	(43,577)	-
Turnover	3,547,529	498,028	(43,577)	4,001,980
Gross profit	2,621,852	307,728	(37,668)	2,891,912
Profit (loss) for the period	982,033	(31,080)	(19,460)	931,493

For the six months ended 30 June 2024

	<u>Integrated Business</u>	<u>Skin Health Business</u>	<u>Elimination</u>	<u>Total</u>
	<u>RMB’000</u>	<u>RMB’000</u>	<u>RMB’000</u>	<u>RMB’000</u>
External revenue	3,395,424	215,645	-	3,611,069
Inter-segment revenue	38,007	28,159	(66,166)	-
Turnover	3,433,431	243,804	(66,166)	3,611,069
Gross profit	2,584,580	158,319	(46,399)	2,696,500
Profit (loss) for the period	978,048	(55,123)	(19,523)	903,402

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(CONTINUED)

FOR THE SIX MONTHS ENDED 30 JUNE 2025

The assets and liabilities of reportable operating segments of the group are analyzed below:

As at 30 June 2025

	Integrated Business	Skin Health Business	Elimination	Total
	RMB'000	RMB'000	RMB'000	RMB'000
Segment assets	19,151,409	2,710,323	(2,924,648)	18,937,084
Segment liabilities	1,667,412	112,842	(8,887)	1,771,367

As at 31 December 2024

	Integrated Business	Skin Health Business	Elimination	Total
	RMB'000	RMB'000	RMB'000	RMB'000
Segment assets	18,521,257	2,175,853	(2,649,320)	18,047,790
Segment liabilities	1,653,722	224,825	(233,865)	1,644,682

4. INCOME TAX EXPENSE

	Six months ended 30 June	
	2025	2024
	RMB'000	RMB'000
Current tax:		
PRC Enterprise Income Tax	124,222	132,256
Hong Kong Profits Tax	1,366	2,493
Macau Complementary Income Tax	60,714	10,888
Dubai Tax	7,198	5,802
Withholding tax	-	85,000
	193,500	236,439
Deferred taxation:		
Current period	19,052	(3,505)
Income tax expense for the period	212,552	232,934

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(CONTINUED)

FOR THE SIX MONTHS ENDED 30 JUNE 2025

5. PROFIT FOR THE PERIOD

	Six months ended 30 June	
	2025	2024
	RMB'000	RMB'000
Profit for the period has been arrived at after charging (crediting):		
Depreciation of property, plant and equipment	23,713	23,330
Amortisation of intangible assets (included in cost of goods sold)	97,751	90,733
Cost of inventories recognised as an expense	1,008,582	820,236
Equity-settled share-based expense	27,310	-
Interest income	(47,841)	(67,066)
Net exchange (gain) loss	(16,771)	2,584

6. DIVIDENDS

During the Reporting Period, a final dividend of RMB 0.1174 per share in respect of the year ended 31 December 2024 (six months ended 30 June 2024: RMB0.0783 per share in respect of the year ended 31 December 2023) was declared and paid to the owners of the Company. The aggregate amount of the final dividend declared and paid during the Reporting Period amounted to RMB284,167,000 (six months ended 30 June 2024: RMB191,991,000).

Subsequent to the end of the interim period, the directors have determined that an interim dividend of RMB0.1555 per share and amounting to RMB376,388,000 (six months ended 30 June 2024: RMB0.1507 per share and amounting to RMB364,171,000) will be paid to the shareholders of the Company.

7. EARNINGS PER SHARE

The calculation of the basic earnings per share attributable to the owners of the Company is based on the following data:

	Six months ended 30 June	
	2025	2024
	RMB'000	RMB'000
Earnings		
Earnings for the purposes of basic earnings per share (profit for the period attributable to owners of the Company)	941,178	910,426
Number of shares		
Weighted average number of ordinary shares for the purpose of basic earnings per share	2,418,526,188	2,438,355,600

No diluted earnings per share for the six months ended 30 June 2025 and for the six months ended 30 June 2024 were presented as there were no potential ordinary shares in issue for both periods.

8. MOVEMENTS IN PROPERTY, PLANT AND EQUIPMENT

During the Reporting Period, the Group spent RMB7,298,000 (six months ended 30 June 2024: RMB4,329,000) on the acquisition of property, plant and equipment in order to upgrade its manufacturing and management efficiency.

9. INTEREST IN ASSOCIATES

	30 June 2025 RMB'000	31 December 2024 RMB'000
Cost of investments in associates		
Listed outside Hong Kong	2,304,356	2,304,356
Unlisted	604,896	479,229
Impairment loss on interest in an associate	(100,000)	(100,000)
Share of post-acquisition profits and other comprehensive income, net of dividends received	725,973	682,399
Exchange adjustments	49,298	23,843
	<u>3,584,523</u>	<u>3,389,827</u>
Fair value of listed investment (Note)	<u>4,433,280</u>	<u>4,416,423</u>

Note: The fair value of the Group's interest in Tibet Rhodiola Pharmaceutical Holding Company ("Tibet Pharmaceutical"), of which its shares are listed on the Shanghai Stock Exchange, was determined on the basis of the quoted market price available on the Shanghai Stock Exchange, which is a level 1 input in terms of IFRS 13.

As at 30 June 2025 and 31 December 2024, details of the associates are as follows:

Name of associates	Place of establishment/ incorporation	Principal place of business	Proportion of ownership interest held by the Group		Principal activities
			30 June 2025	31 December 2024	
Tibet Pharmaceutical	PRC	PRC	37.36%	37.36%	Production of medicines and sale of drugs
Shenzhen Kangmai Biotechnology Co., Ltd.	PRC	PRC	50.00%	50.00%	Research and development of antibodies medicines
Eye Tech Care ("ETC")	France	France	36.17%	36.17%	Research and development of therapeutic ultrasound device
PharmaGend Global Medical Services Pte. Ltd	Singapore	Singapore	45.00%	45.00%	Production of medicines and sale of drugs
Higend Sciences Limited	Cayman Islands	Singapore	50.00%	-	Research and development of medicines

10. TRADE AND OTHER RECEIVABLES AND PREPAYMENTS

	30 June 2025 RMB'000	31 December 2024 RMB'000
Trade receivables	1,451,789	1,232,012
Less: allowance for credit losses	(9,665)	(9,533)
	<hr/>	<hr/>
	1,442,124	1,222,479
Bills receivables	178,560	198,805
Purchase prepayment	260,315	204,617
Other receivables and deposits	167,719	154,582
	<hr/>	<hr/>
	2,048,718	1,780,483
	<hr/>	<hr/>

The Group normally allows a credit period ranging from 0 to 90 days to its trade customers, but longer credit period up to four months is allowed to some selected customers.

An aging analysis of the trade receivables (net of allowance for credit losses) presented based on the dates of receipt of goods at the respective reporting dates, which approximated the respective revenue recognition date, is as follows:

	30 June 2025 RMB'000	31 December 2024 RMB'000
0 - 90 days	1,403,354	1,186,892
91 - 365 days	38,770	35,587
	<hr/>	<hr/>
	1,442,124	1,222,479
	<hr/>	<hr/>

The bills receivables of the Group are of the age within six months at the end of the Reporting Period.

11. AMOUNT DUE FROM ASSOCIATES

As at 30 June 2025, the balance of approximately RMB30,000,000 (31 December 2024: RMB30,000,000) was non-trade nature and non-interest bearing, represented deposit to Tibet Pharmaceutical for an exclusive distribution right.

As at 30 June 2025, the balance of approximately RMB475,014,000 (31 December 2024: RMB284,088,000) was trade nature and non-interest bearing, represented promotion income receivables from Tibet Pharmaceutical and ETC. The Group allows a credit period of 90 days to associates. The balance as at 30 June 2025 was aged within three months (31 December 2024: within three months) based on the invoice date.

12. TRADE AND OTHER PAYABLES

An aging analysis of the trade payables presented based on the invoice date at the end of the Reporting Period is as follows:

	30 June 2025 RMB'000	31 December 2024 RMB'000
0 - 90 days	133,171	135,883
91 - 365 days	3,136	4,212
Over 365 days	1,009	2,337
Trade payables	137,316	142,432
Payroll and welfare payables	243,965	214,922
Other tax payables	47,870	27,416
Accrued promotion expenses	118,655	26,315
Accruals	66,703	61,232
Other payables	24,211	12,480
	<u>638,720</u>	<u>484,797</u>

The credit period on purchases of goods ranges from 0 to 120 days.

13. BANK BORROWINGS

	30 June 2025 RMB'000	31 December 2024 RMB'000
Bank loans	<u>715,000</u>	<u>831,300</u>
Analysed as:		
Unsecured	<u>715,000</u>	<u>831,300</u>
Classified as:		
Current liabilities	<u>715,000</u>	<u>831,300</u>

During the Reporting Period, the Group's bank borrowings decreased by a net amount of RMB116,300,000 (six months ended 30 June 2024: decreased by a net amount of RMB163,125,000), the weighted average interest rate of loans was 2.3% (six months ended 30 June 2024: 3.3%) per annum.

14. SHARE CAPITAL

	Number of shares '000	Amount RMB'000
Authorised share capital: At 31 December 2024 and 30 June 2025	20,000,000	765,218
Issued and fully paid: At 31 December 2024 and 30 June 2025	2,439,529	83,564

On 28 March 2025, the Company granted 3,973,400 of its shares with a fair value of RMB27,310,000 at the grant date, to employees who have made outstanding contributions to the launch of new products. On 31 March 2025, 3,973,400 shares were fully vested. Accordingly, RMB27,310,000 was recognised in profit or loss and the cost of RMB27,286,000 was deducted from treasury stock, the difference of RMB24,000 was credited into share premium.

15. FAIR VALUE MEASUREMENTS OF FINANCIAL INSTRUMENTS

Fair value of the Group's financial assets and financial liabilities that are measured at fair value on a recurring basis

Some of the Group's financial assets and financial liabilities are measured at fair value at the end of each reporting period. The following table gives information on how the fair values of these financial assets and financial liabilities are determined (in particular, the valuation techniques and inputs used), as well as the level of the fair value hierarchy into which the fair value measurements are categorised (levels 1 to 3) based on the degree to which the inputs to the fair value measurements are observable.

- Level 1 fair value measurements are those derived from quoted prices (unadjusted) in the active market for identical assets or liabilities;
- Level 2 fair value measurements are those derived from inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and
- Level 3 fair value measurements are those derived from valuation techniques that include inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(CONTINUED)

FOR THE SIX MONTHS ENDED 30 JUNE 2025

Financial instruments	Fair value as at		Fair value hierarchy	Valuation techniques and key inputs	Significant unobservable inputs
	30/06/2025	31/12/2024			
1) Equity instruments at FVTOCI - listed	Listed equity securities on stock exchanges - nil	Listed equity securities on stock exchanges - RMB 20,000	Level 1	Quoted bid prices in an active market.	Nil
2) Equity instruments at FVTOCI - unlisted	Unlisted equity investments - RMB 130,416,000	Unlisted equity investments - RMB 129,763,000	Level 3	Market approach by applying market multiples such as the ratio of market capital to net book value from comparable companies.	The ratio of market capital to net book value from comparable companies
3) Financial asset at FVTPL - listed	Listed equity securities on the HKEX - RMB1,442,000	Listed equity securities on the HKEX - RMB2,474,000	Level 1	Quoted bid prices in an active market.	Nil
4) Financial asset at FVTPL - capital funds	Assets - RMB 1,067,968,000	Assets - RMB 926,124,000	Level 3	Direct comparison - reference to market evidence of recent transaction prices of the underlying investments.	Recent transaction prices of underlying investments
5) Financial asset at FVTPL - unlisted	Assets - RMB 1,254,932,000	Assets - RMB 981,291,000	Level 2	Recent Transaction method, quoted bid prices in an inactive market.	Nil
6) Financial asset at FVTPL - unlisted	Assets - RMB 189,761,000	Assets - RMB 250,208,000	Level 3	Market approach by applying market multiples such as the ratio of market capital to net book value from comparable companies.	The ratio of market capital to net book value from comparable companies

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(CONTINUED)

FOR THE SIX MONTHS ENDED 30 JUNE 2025

Reconciliation of Level 3 fair value measurements

	Equity instruments at FVTOCI RMB'000	Financial assets at FVTPL RMB'000	Total RMB'000
As at 1 January 2024	125,344	1,319,120	1,444,464
Purchases	-	61,589	61,589
Total gains			
- in profit or loss	-	463	463
- in other comprehensive income	(49,503)	-	(49,503)
As at 30 June 2024	75,841	1,381,172	1,457,013
As at 1 January 2025	129,763	1,176,332	1,306,095
Purchases	-	133,681	133,681
Transfer to level 2 from level 3	-	(55,913)	(55,913)
Total gains			
- in profit or loss	-	3,629	3,629
- in other comprehensive income	653	-	653
As at 30 June 2025	130,416	1,257,729	1,388,145

Fair value of the Group's financial assets and financial liabilities that are not measured at fair value on a recurring basis

The directors of the Company consider that the carrying amounts of financial assets and financial liabilities recorded at amortised cost in the condensed consolidated financial statements approximate their fair values.

16. CAPITAL COMMITMENTS

	30 June 2025 RMB'000	31 December 2024 RMB'000
Capital expenditure in respect of the acquisition of below items contracted for but not provided in the condensed consolidated financial statements		
- financial assets at FVTPL	446,482	576,499
- interest in an associate	34,541	34,541

17. RELATED PARTY TRANSACTIONS

Balances and transactions between the Company and its subsidiaries, which are related parties of the Company, have been eliminated on consolidation and are not disclosed in this note. Details of transactions between the Group and other related parties are disclosed below, in addition to the transactions and balances disclosed elsewhere in the condensed consolidated financial statements.

- (a) The Group entered into the following transactions with related parties during the Reporting Period:

Name of related company	Relationship	Nature of transactions	Six months ended 30 June	
			2025 RMB'000	2024 RMB'000
Tibet Pharmaceutical	Associate	Promotion income	834,632	830,701
ETC	Associate	Purchase of goods	-	5,556
ETC	Associate	Promotion income	3,453	5,642
Shenzhen Mediportal Health Medical Internet Limited	Related party	Service fee	257	630
Shenzhen Mediportal Health Technology Co., Ltd.	Related party	Service fee	1,515	-
A&B (HK) Company Limited	Related party	Royalty expenses	805	1,423

- (b) On 20 August 2018, the Group entered into a framework asset transfer agreement with A&B relating to the pharmaceutical preparation, formulation, dosage form, or delivery vehicle, containing or comprising NRL-1 etc. and/or line extensions developed by or for Neurelis, Inc. ("Neurelis") (collectively, the "Product of NRL-1"). Neurelis is one of Group's unlisted equity investments. According to terms of such agreement, the Group has agreed to acquire from A&B all assets related to the Product of NRL-1 (the "Assets of NRL-1") in the Territory (the "Transaction of NRL-1"). A&B obtained the Assets of NRL-1 from its related entity which in turn obtained the Assets of NRL-1 from Neurelis. As at 31 December 2023, the Group and A&B had negotiated and agreed on the terms of the Transaction of NRL-1, the Group has agreed to pay A&B a royalty payment of up to US\$0.6 per Unit of NRL-1 imported into or sold in the Territories, and the Group has agreed to pay A&B a royalty payment of 9.0% on the net sales of NRL-1 sold by the Group in the Territories. The Group has accrual amount of RMB805,000 (six months ended 30 June 2024: RMB1,423,000) of royalty expense during six months ended 30 June 2025.
- (c) The remuneration of key management personnel during the Reporting Period amounted to RMB7,121,000 (six months ended 30 June 2024: RMB8,550,000).